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Abstract 
Specific mutants were developed to evaluate the roles of several residues in α8 helix of 
the regulatory (R) domain of human pyruvate dehydrogenase kinase 2 (PDHK2) in the linkage 
between the Regulatory (R) and catalytic (Cat) domain (Q144A), dichloroacetate 
(DCA)/pyruvate inhibition (R154C, R158A, I157F) and stimulation by reductive acetylation 
(L160A, R154C/L160A). All mutants, with the exception of L160A, were active, and were 
bound to and had their activities enhanced by dihydrolipoyl acetyltransferase (E2). The cross 
arms between subunits are anchored by W383. Based on the studies on the W383F mutant, 
W383 provided majority of the intrinsic Trp fluorescence; and ligand(s) binding quenched 
primarily (pyruvate) or exclusively (ADP or ATP) the fluorescence of W383. 
The Q144 mutation in the R domain caused 14-fold weaker K+ binding with ATP in the 
Cat domain but did not alter the weaker K+ binding with ADP unless Pi was included. Similarly, 
with 100 mM K+, the Q144A mutant had weaker ATP binding but the affinity for ADP was not 
changed even in the presence of Pi, which enhanced the binding of ADP to kinase by 2-fold.  
R154 and R158 were shown to be important residues in the inhibition by pyruvate, DCA 
and Cl-. The R154C, R154C/L160A and R158A mutations reduced the inhibition by DCA or 
pyruvate using E1 or E1•E2 as the substrates. Pyruvate plus ADP did not significantly hinder the 
binding of GST-L2 to these mutants in AUC studies. Cl- appears to bind to kinase at the same 
site as DCA/pyruvate based on lack of Cl- effects with above mutants and evidence that Cl- 
weakened the inhibition by DCA or pyruvate of native PDHK2. 
 Q144 and L160 may play important roles in the signal transmission from the lipoyl 
group-binding site to the active site. Q144A and R154C/L160A mutants were less stimulated by 
reductive acetylation than other mutants and native PDHK2. Nov3r binds to where lipoyl goup 
binds PDHK2. Using E1 alone as substrate, Nov3r binding caused a 20% increase of kinase 
activity at low levels. Nov3r binding also reduced the inhibition of DCA/pyruvate with elevated 
K+ plus Pi.  
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Abstract 
Specific mutants were developed to evaluate the roles of several residues in α8 helix of 
the regulatory (R) domain of human pyruvate dehydrogenase kinase 2 (PDHK2) in the linkage 
between the Regulatory (R) and catalytic (Cat) domain (Q144A), dichloroacetate 
(DCA)/pyruvate inhibition (R154C, R158A, I157F) and stimulation by reductive acetylation 
(L160A, R154C/L160A). All mutants, with the exception of L160A, were active, and were 
bound to and had their activities enhanced by dihydrolipoyl acetyltransferase (E2). The cross 
arms between subunits are anchored by W383. Based on the studies on the W383F mutant, 
W383 provided majority of the intrinsic Trp fluorescence; and ligand(s) binding quenched 
primarily (pyruvate) or exclusively (ADP or ATP) the fluorescence of W383. 
The Q144 mutation in the R domain caused 14-fold weaker K+ binding with ATP in the 
Cat domain but did not alter the weaker K+ binding with ADP unless Pi was included. Similarly, 
with 100 mM K+, the Q144A mutant had weaker ATP binding but the affinity for ADP was not 
changed even in the presence of Pi, which enhanced the binding of ADP to kinase by 2-fold.  
R154 and R158 were shown to be important residues in the inhibition by pyruvate, DCA 
and Cl-. The R154C, R154C/L160A and R158A mutations reduced the inhibition by DCA or 
pyruvate using E1 or E1•E2 as the substrates. Pyruvate plus ADP did not significantly hinder the 
binding of GST-L2 to these mutants in AUC studies. Cl- appears to bind to kinase at the same 
site as DCA/pyruvate based on lack of Cl- effects with above mutants and evidence that Cl- 
weakened the inhibition by DCA or pyruvate of native PDHK2. 
 Q144 and L160 may play important roles in the signal transmission from the lipoyl 
group-binding site to the active site. Q144A and R154C/L160A mutants were less stimulated by 
reductive acetylation than other mutants and native PDHK2. Nov3r binds to where lipoyl goup 
binds PDHK2. Using E1 alone as substrate, Nov3r binding caused a 20% increase of kinase 
activity at low levels. Nov3r binding also reduced the inhibition of DCA/pyruvate with elevated 
K+ plus Pi.  
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Characterization of human pyruvate dehydrogenase kinase  
isoform 2 (PDHK2) 
Chapter 1 
General Introduction 
PDC reaction and its components 
The mitochondrial pyruvate dehydrogenase complex (PDC) catalyzes the irreversible 
oxidative decarboxylation of pyruvate to acetyl-CoA (Fig. 1-1). It results in the irreversible loss 
of glucose carbon and controls the metabolic fate of pyruvate acid and carbohydrate fuels in 
general as animals lack the means of converting acetyl-CoA to glucose (1, 2, 3). The PDC 
reaction connects glycolysis to oxidative metabolism to provide the oxidative fuel for the 
generation of ATP. The PDC reaction also provides acetyl-CoA for fatty acids synthesis in fat 
synthesizing tissues when carbohydrate intake is excessive. 
Mammalian PDC is a huge complex with several components: pyruvate dehydrogenase 
(E1), dihidrolipoyl transactylase (E2), E3 binding domain (E3BP) and dihydrolipoyl 
dehydrogenase (E3) (see Table 1-1) (1). E1 catalyzes the irreversible first step of PDC reaction 
(4, 5) and also the second step (Fig. 1-1). It decarboxylates pyruvate and forms 
hydroxyethylidene-TPP intermediate (step 1), followed by reductive acetylation of lipoamide 
group of the E2 to form acetyl-dihydrolipoamide-E2 (step 2). E2 then catalyzes the transfer of 
acetyl group to CoA to form acetyl-CoA and dihydrolipoamide-E2 (step 3). E3 oxidizes 
dihydrolipoamide group back to lipoamide using a tightly bound FAD group on E3 (step 4). 
Finally, reduced E3 is re-oxidized with the transferring of protons and electron to NAD+ to form 
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NADH (step 5). The PDC reaction exemplifies how intermediate channeling in a multi-enzyme 
system can achieve high efficiency of catalysis. The lipoyl-lysyl arm and flexible linker regions 
of E2 and E3BP give mobility for intermediate carrier to access directly the active sites of E1 
and E3, therefore greatly enhancing the efficiency of reactions. 
E1 is a hetero-tetramer with two α subunits and two β subunits (4, 5). E1 has two active 
sites, each is located between one α subunit and one β subunit. In each active site, there is a non-
covalently bound thiamine pyrophosphate (TPP) cofactor and a Mg2+ ion. The active sites of E1 
are chemically equivalent but catalysis proceeds asynchronously at the two active sites. Kinetic, 
crystallographic, and spectroscopic evidence supports an alternating-site mechanism for E1 (4-
7). Crystal structure of B. stearothermophilus E1 reveals a solvated tunnel containing four Asp 
and six Glu residues, which connects the two active sites. This acidic tunnel can serve as a 
proton wire to shuttle a proton from one active site to another. This proton-wire mechanism is 
also proposed to explain “half of the sites” phenomena in E1 reaction (4). A flip-flop mechanism 
has also been suggested in which the two active sites affect each other and perform alternate 
phases of the catalytic reaction at given moment (5-7). The major difference between these two 
alternative mechanisms is that communication of active centers is linked either to proton transfer 
with no major structural changes in the proton-wire mechanism or to structural changes that 
switch on or off the alternative active site in the flip-flop mechanism. 
The core of mammalian PDC is an integrated structure formed by association of the 
multi-domain E2 and E3-binding protein (E3BP). E2 subunits have four globular domains: inner 
domain (I) in the C-terminal end, E1 binding domain, and two lipoyl domains (L1 and L2) in the 
N-terminus (Fig. 1-2) (8). E3BP has single lipoyl domain (L3) at its N-terminus, a C-terminal 
inner domain (I’) and E3 binding domain (B’) between them (9). These globular domains of E2 
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and E3 are connected by flexible linkers or hinge regions that make it easy for rapid and flexible 
movement. Yeast E2 forms a pentagonal dodecahedron 60mer using I domains and I’ domains of 
E3BP associate with this inner core (10). Based on small-angle X-ray scattering, cryoelectron 
microscopy and analytical sedimentation analyses, a model for the inner core of human E2-E3BP 
(also called E2BP) was proposed to be composed of 48 E2 I domains and 12 E3BP I’ domains 
while keeping the dodecahedron shape and symmetry (11). The lipoyl groups of lipoyl domains 
varied between oxidized, reduced or acetylated forms during PDC reactions. The lipoyl domains 
also bind to PDHK and PDHP isoforms (Fig. 1-2) and play important roles in their regulation (8-
10). 
PDC activity regulation 
PDC activity is firmly controlled so tissues can adjust to different energy sources (1-3, 
12). When there is abundant carbohydrate, PDC is activated for tissues to use glucose as the 
energy source (2). While under starvation conditions, PDC activity is down regulated to lower 
the use of glucose in most tissues to conserve glucose for use by neural tissues, which use 
glucose as the major energy sources. PDC activity is also down regulated in animals that are fed 
a high fat diet (3). 
E1 catalyzes an irreversible and rate-limiting step in pyruvate reaction (4, 5). It is the 
major target in the regulation of PDC activity. The primary means of control of PDC activity is 
by the co-valent modification of E1 (13-16). Pyruvate dehydrogenase kinase (PDHK) 
phosphorylates α subunit of the E1 tetramer to inactivate it. Pyruvate dehydrogenase 
phosphatase (PDHP) dephosphorylates inactive E1 to recover PDC activity (Fig. 1-3). 
There are 4 isoforms of human PDHK and two isoforms of human PDHP (Table 1-1) 
(17-21). PDHK1 is expressed in heart, pancreatic islets and skeleton muscle (17-21). PDHK2 is 
 4 
widely distributed in heart, liver, kidney and most other organs (17-21). Distribution of PDHK3 
is relatively limited. It is expressed in testis, kidney and brain (17-21). There is low endogenous 
PDHK4 in heart, skeletal muscle, liver, kidney and pancreatic islet that is increased when 
carbohydrate stores are reduced (18). PDHP1 is expressed in most tissues. It needs Mg2+ and is 
stimulated by Ca2+ (20, 22, 23). PDHP2 is expressed in liver, kidney, brain and heart. It is not 
activated by Ca2+ (20). 
There are three serine residues in each α subunit of E1 that can be phosphorylated by 
PDHKs: Serine 264 (site 1), Serine 271 (site 2) and Serine 203 (site 3) (24). Phosphorylation of 
only one site in an E1 tetramer (total six potential phosphorylation sites) causes inactivation of 
E1 demonstrating half-of-the-sites-inactivation (6, 25). Using mutants E1 with only a single site 
available to be phosphorylated, site-specificity and phosphorylation rates were measured for 
individual PDHK isoform (14, 16, 26, 27). Site 1 and 2 can be phosphorylated by all PDHK 
isoforms, while site 3 can only be used efficiently by PDHK1. All PDHK isoforms, apart from 
PDHK3, have higher rates of phosphorylation of site 1 than site 2.  For site 1, the relative rates of 
phosphorylation are in the order PDHK2>PDHK4>PDHK1 >PDHK3. For site 2, the relative 
rates of phosphorylation are in the order PDHK3> PDHK4> PDHK2>PDHK1. The rate of 
phosphorylation on site 3 by PDHK1 is close to its rate on site 2 but far slower than on site 1. 
Using native E1 as substrate, Kasten S.A. found that both PDHK3 and PDHK2 had higher 
activity (7 fold and 20 fold) on site 1 than on site 2. There was also significantly more 
phosphorylation at site 2 by PDHK3 than PDHK2 in the presence of E2, although 
phosphorylation at site 2 was relatively slow for both kinases in the absence of E2 (Kasten, S.A. 
PhD thesis). All sites were shown to be phosphorylated to a different extent with more 
phosphorylation of site 1 and less phosphorylation of site 2 and 3 in vivo (28). Both PDHP1 and 
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PDHP2 can remove the phosphates from all three sites with the order of dephosphorylation rates 
site 2 > site 3 ≈ site 1 using mutant E1 as substrate (20).  
E2 influence on PDHK activity 
 E2 plays important roles in the functional regulation of PDHK activity (8, 29). Using 
micromolar levels of E1, PDHK2 activity is enhanced several fold in the presence of E2. The 
enhancement of PDHK2 activity by E2 was greatly increased when nM levels of E1 were used 
(~5000 fold) (Hiromasa, Y. et. al., unpublished data from our lab). To accomplish this, PDHK 
must be bound by lipoyl domains of E2. PDHK activity is enhanced because an E2-bound kinase 
greatly gains in access to E2-bound E1. When ΔBE2 (E2 constructs with E1 binding domain 
deleted) is used, there is only a 22% increase in PDHK2 activity (30). Different PDHK isoforms 
have different binding preferences for different lipoyl domain and activity enhancement (Fig. 1-
2) (31-39). PDHK1 can bind to both L1 and L2 domain in E2. Bovine kidney PDHK2 prefers to 
bind to L2 domain of E2. Human PDHK2 also preferred to bind to L2 with increased activity 
(32, 34). Purified PDHK3 is not stable and tends to self-associate. L1 has minimal influence on 
PDHK3 activity. GST-L1 causes 2-fold activity increase. Both L2 and GST-L2 enhance PDHK3 
activity 7-8 -fold comparing with 17-fold activation by E2 (32). Hiromasa, Y., et. al. found that 
PDHK3 could be a stable dimer at 4 °C by using freshly prepared PDHK3 and removing 
aggregate by gel-filtration (unpublished data from our lab). This form of PDHK3 was very active 
but underwent a lesser activity enhancement by GST-L2 or E2. These findings suggests that 
PDHK3 that undergoes significant activity enhancement by L2 contains abundant aggregates that 
are prevented or reversed by binding to L2 to contribute to the large enhancement of activity. In 
agreement with this, L2•PDHK3 is a stable dimer (Peng, T. PhD thesis). Human PDHK4 has the 
highest activity with E1 alone among all PDHK isoforms (Dong, J. PhD thesis). 
 6 
PDHK regulation 
There are two kinds of regulation of PDHK activity: short-term control and long-term 
control (2). In short-term control, small molecular effectors including the substrate and products 
of PDC reaction directly influence the activity of PDHK (Fig. 1-3). In long-term control, the 
mRNA and protein levels of PDHK are regulated. 
Among all PDHK isoforms, PDHK2 is the most responsive isoform to the known 
effectors (19, 21, 30, 32, 40). Pyruvate, substrate of PDC reaction, directly binds and inhibits 
PDHK2 activity. Catalysis by TPP-loaded E1 involving either partial reactions or the first two 
steps of PDC reaction deplete pyruvate and produce intermediates that affect PDHK activities 
(below). DCA (dichloridacetate), an analog of pyruvate (41), is widely used to study inhibition at 
this site in PDHK because DCA cannot be used as substrate by E1 (42, 43). In comparison to 
PDHK2, the activity of PDHK3 is relatively insensitive to pyruvate inhibition (21, 32). Human 
PDHK4 is sensitive to DCA inhibition (Dong, J., PhD thesis). Elevated ADP and Pi levels, 
indicators of a lowered energy state, inhibit the activities of PDHK isoforms (32). ADP 
dissociation appears to be the rate-limiting step of PDHK2 reaction in the presence of E2. ADP 
plus DCA or pyruvate (using E1 free of TPP) show coupled binding and synergistically inhibit 
PDHK2 (40). 
NADH and acetyl-CoA, products of the PDC reaction and also fatty acid oxidation, 
stimulate PDHK activity. When fatty acid oxidation produces abundant NADH and acetyl-CoA, 
this stimulation of PDHK activity down-regulates PDC activity (2). NADH nearly doubles 
PDHK2 activity through reducing lipoyl groups of E2. AUC data demonstrate that lipoyl 
domains with reduced prosthetic groups bind tighter to PDHK2 (34). NADH plus acetyl-CoA 
support more than 3.5-fold stimulation of PDHK2 by reductive acetylation of lipoyl groups. 
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Reductive acetylation speeds up the dissociation of ADP to increase PDHK2 activity (30). 
NADH and acetyl-CoA also stimulate PDHK1 but increase PDHK3 activity only in the presence 
of ADP (32). Our work on PDHK4 show that there is no NADH and acetyl-CoA stimulation on 
modified human PDHK4, in which Gly-Glu-Glu residues are added to its C-terminus. NADH 
and acetyl-CoA stimulation is found using unmodified PDHK4 (Dong, J., PhD thesis). These 
data suggest that the C-terminal region plays an important role in the stimulation of PDHK 
activity by reductive acetylation. 
In the long-term control, mRNA and protein levels of PDHK isoforms vary in response to 
nutritional states and endocrine manipulations. The combination of up-regulation of PDHK and 
short-term stimulation of PDHK activity decrease the activity of PDC in order to conserve 
glucose for the brain and other central neural system. Expression of PDHK2 is increased in liver 
(44, 45) and kidney (45, 46) during starvation. PDHK4 mRNA is increased 2 to 4- fold in the 
kidney, liver, white adipose tissue, and brain of starved rats (45, 47). PDHK4 is the major 
isoform over-expressed in muscle tissues (3, 48-52). Up-regulation of PDHK4 is also observed 
in rats fed a high fat (low carbohydrate) diet (3, 16, 53), and due to diabetes (48, 54, 55) or 
carnitine deficient rats (56). Transcription of PDHK4 is rapidly activated before those genes 
involved in fatty acids metabolism when mice are treated with fibrates, which are used clinically 
to reduce triglyceride levels (57). Apart from the increased expression of PDHK4, PDHP2 levels 
are also lowered in heart and kidney of starved rats (58). Re-feeding of starved rats decreases the 
PDHK4 mRNA level and protein amount of PDHK4 portion in heart (46). Insulin treatment of 
diabetic rats reduces PDHK4 mRNA and protein to non-diabetic levels. Insulin has no effect on 
PDHK1 but causes small decreases in heart PDHK2 levels in diabetic rats (46).  
PDHK4 gene control 
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PDHK4 is the major target of long-term control of PDHK (see above). Histone 
deacetylase inhibitors retinoic acid and trichostain A increase the transcription of human PDHK4 
(59, 60). Peroxisome proliferator-activated receptors (PPARα, δ, β/δ), lipid-activated 
transcriptional factors involved in lipid storage and catabolism, are suggested to be involved in 
PDHK4 gene regulation. Glucocorticoids dexamethasone and WY 14,643 (an agonist of 
PPARα) promote expression of PDHK4 (61, 62). PPARα mRNA level is 7-17 fold enriched in 
heart and liver of starved mice. The capacity of starvation to induce increases of heart and liver 
PDHK4 is less in PPARα knockout mice than in wild type mice. However, there is no difference 
in the starvation-induced increase of expression of skeletal muscle PDHK4 (63). A highly 
selective PPARδ agonist also increased expression of PDHK4 (63, 64). siRNA for PPARβ/δ 
gene significantly reduced transcription of PDHK4 (90%), PDHK2 (33%) and PDHK3 (21%) 
(65). The level of peroxisome proliferators-activated receptor gamma co-activator (PGC-1α), a 
transcriptional co-activator of PPARγ, is elevated in diabetic rat liver, leading to increasing 
mitochondrial biogenesis and speeding up fatty acid oxidation. PGC-1α elevates PDHK4 
transcription by 14-fold (possibly through PPARα but not PPARγ) (66). Hepatic nuclear factor-4 
(HNF4), a nuclear glucocorticoid receptor (GR) that interacts with PGC-1α, also stimulates both 
rat and mouse PDHK4 gene transcription (66). A model (Fig. 1-4) is proposed to explain the 
glucocorticoid-induced stimulation and insulin inhibition of transcription of PDHK4 (67). There 
are two glucocorticoid response elements (GRE) and three insulin response sequences (IRS) in 
the human PDHK4 promoter. When treated with glucocorticoid, activated GR is translocated 
into the nucleus to recruit P300/CBP complex (histone acetyltransferases). The whole complex 
then binds to GRE in PDHK4 promoter through dimerized GR. At the same time, P300/CBP 
complex also binds to FOXO (Forkhead Box factors) that in turn binds to IRS (Fig. 1-4A). The 
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whole complex stimulates the transcription of PDHK4. Insulin prevents the binding of FOXO to 
IRS, breaking the complex to decrease the transcription of PDHK4 (Fig. 1-4B). 
PDHK structure 
PDHK isoforms add phosphate to serine residues in E1. However, PDHK isoforms lack 
the characteristic structural motifs of general eukaryotic serine/threonine kinases (18, 68-70). 
Instead they are more like bacterial histidine kinases (70-75). PDHK monomer can be divided 
into two domains: N-terminal regulatory domain (R domain) and C-terminal catalytic (Cat) 
domain (75). In human PDHK2 (76), the R domain includes residues 1 to 171. It contains 8 α 
helices connected by flexible loops. There is a flexible loop from Ser171 to Pro177 that connects 
the R domain to the Cat domain. The Cat domain (178-360) of PDHK2 is an αβ mixed 
secondary structure (74, 76). There are five β-strands, which form a single β-sheet.  
PDHK2 is a dimer in solution (33, 34). The crystal structures of human (76) and rat (74) 
PDHK2 show that the major contacts supporting dimerization are formed between the β-sheet 
regions of Cat domain of two monomers (Fig. 1-5). Interactions between helix α11 and the loop 
connecting β5 and β6 from the other subunit also contribute to dimer formation. The C-terminal 
tail beyond the Cat domain can also contribute to the formation of dimer in human PDHK2. Each 
C-terminal tail (from residues Val 360 to Cys 384) first extends along the R domain of the same 
subunit and then forms a cross arm extending across to the other subunit (Fig. 1-5) (76). Trp383 
from one tail is inserted between Arg 362 on same C-terminal tail and Arg 149 (on helix 8) of 
the other subunit. Residue Cys 384 from one tail is sandwiched between Pro 22 (on loop between 
helix 1 and helix 2) and Val 365 (on C-terminal tail) of the other subunit. These interactions act 
to anchor the cross arm. In the crystal structure of rat PDHK2•ADP (74) and human 
PDHK2•ADP•DCA (76), the cross arms were not resolved. 
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At the ends of the PDHK2 dimer, there is a large solvent exposed cleft between the R and 
Cat domains within each subunit that contains the active site of PDHK2 (74, 76). At the bottom 
of the cleft, helices α7 and the C-terminus of α8 of the R domain form one side of a groove and 
the N-terminus of helix α10 and helix α12 from Cat domain form the other side of the groove.  
The ATP or ADP binding sites are formed by segments from the Cat domain β-sheet, α 
helices and loops (Fig. 1-6). A conserved G1 box (Asp-282-X-Gly284-X-Gly286) on the loop 
connecting β6 and α11 binds to the adenine part of ADP or ATP. Another conserved motif, G2 
box (Gly317-X-Gly319-X-Gly321), located in the C-terminal end of the loop connecting helices 
α11 and α12, forms parts of the catalytic site through binding of α and β phosphate of ADP or 
ATP. A third conserved N-box (Glu243-X-X-Lys246-Asn247) on helix α10 binds to the Mg2+ 
ion using Asn247, Glu243 and two water molecules. Human PDHK2 was crystallized under 
conditions that included minimal K+ (76). Crystal structures of related branch-chain α-ketoacid 
dehydrogenase (BCKD) kinase (72) and PDHK3 (77-79) show that a K+ ion is involved in 
nucleotide binding. Knoechel et. al. proposed that a K+ ion is also located  in the catalytic site of 
PDHK2 (see below) (76).  
The overall crystal structure obtained for PDHK3 is similar to PDHK2 (77). The crystal 
structure of PDHK3/L2 also resolved how lipoyl domain bound to kinase. The lipoyl domain 
binding includes both hydrophobic interactions in the lipoyl prosthetic group binding pocket and 
electrostatic interactions in the other parts of the R domain and also helix α13 of the C-terminal 
tail. The hydrophobic pocket for lipoyl group binding is formed mainly by helices α1/α2, the 
loop connecting them and also the C-terminus of helix α8. Residues 389 to 393 of the C-terminal 
tail from the other subunit are also part of this pocket. Substitutions of residues in this pocket 
(Leu19A, Phe27A and Phe40A) weaken the binding affinity for L2 and the activity of kinase 
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were less enhanced by L2 (79). The electrostatic interactions are formed by positive residues of 
the helices α1/α13 with acidic residues in the lipoyl domain. These positive residues (Arg13, 
Lys366 and Arg370) are conserved or replaced by other positive charged residues in all PDHK 
isoforms. They form electrostatic interactions with the acidic residues on L2 (Glu162, Asp164, 
Glu179, Glu182 and Glu183). Mutation of Glu162 and Glu179 on L2 weakened the binding of 
L2 to PDHK3 and decreased the capability of L2 to activate PDHK3 (79) as previously reported 
(8).  
The resolution of the C-terminal tail of PDHK3 (77) is informative because the C-
terminal tail beyond Cys384 of PDHK2 is not resolved for rat (74) and human PDHK2 (76). 
Residues 378 to 383 of the C-terminal tail of one subunit form several hydrogen bonds with 
conserved residues of the other subunit in the PDHK3 dimer. There are two important hydrogen 
bonds formed by Asn383 with Asp399 in the same subunit and Ser382 from one subunit with 
Leu361 on the other subunit. Both hydrogen bonds are eliminated in other PDHK isoforms with 
substitution of Ser382 by cysteine and Asp399 by valine or isoleucine, as the side chain of 
cysteine is a poor hydrogen donor and valine or isoleucine are unable to form hydrogen bonds.  
Residues 384 to 389 make contacts with L2 residues around lipoyl-Lys173 in PDHK3. 
Arg389 of PDHk3 can form 2 hydrogen bonds with Asp172 on L2 instead of a possible single 
hydrogen bond as lysine replaces Arg389 in other PDHK isoforms. Three interactions involving 
the C-terminal tail with structural adjacent groups help to stabilize the C-terminal region from 
389 to 393 that are part of the lipoyl group binding pocket: 1) Hydrogen bond between Arg389 
and Gln23, 2) Hydrogen bond between Ser392 and Asp30, and 3) Electrostatic interaction 
between Asp390 and Lys393. In other PDHK isoforms, some or all of these residues are 
substituted by residues that cannot maintain these interactions. Therefore their binding to lipoyl 
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domains would be weakened as it is found that PDHK3 has the highest binding affinity to L2 (8, 
32, 33). The importance of the C-terminal tail in the tighter binding of PDHK3 to L2 was 
demonstrated with a series of deletions in this region (79). Deletion of PDHK3 from Glu387 to 
the C-terminus resulted in significantly weaker binding between PDHK3 and L2. Further 
deletion (from 384 to 366) almost abolished the binding of PDHK3 to L2. Although the C-
terminal tail of PDHK2 was not resolved (74, 76), it is important for the activation of PDHK2 by 
E2. Deletion of the C-terminal tail from 386 to the C-terminus abolished the activation of 
PDHK2 by E2 (37). 
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Research focus 
Previous studies on PDHK indicated that elevated K+ and Pi significantly altered the 
capacity of effectors to influence the kinase activity (32). Elevated K+ lowers the Km for ATP 
with an equivalent decrease in kcat and causes stronger inhibition by ADP and DCA (40, 80). 
Steady-state kinetic studies indicated that pyruvate/DCA bind efficiently to the PDHK2•ADP 
intermediate while also bind to the PDHK2•ATP (40). Fluorescence quenching studies found 
that ADP bound tighter in the presence of pyruvate or DCA while pyruvate/DCA binding were 
also much tighter in the presence of ATP or ADP (43). The combination of pyruvate plus ADP 
greatly weakens the binding of the lipoyl domain to PDHK2 (43). NADH and acetyl-CoA 
stimulation by reductive acetylation of L2 requires elevated K+ and Cl- ions and is enhanced by 
Pi (30, 32). But the molecular mechanism supporting the communication between the catalytic 
site, the DCA/pyruvate binding site and the lipoyl domain-binding site was not understood. As 
previous studies on PDHK2 generally used E1•E2 as substrate, it is not clear how those 
interactions influence the PDHK2 activity. Using E1 alone as substrate would eliminate the E2 
interference. It is also not clear how K+ or Cl- influences the activity of PDHK2. At the same 
time, although a DCA binding site is indicated in the crystal structure of human 
PDHK2•ADP•DCA, it has not been established whether this site represents a physiologically 
functional DCA-binding pocket or which residues are most important for binding. 
The specific aims of this thesis include: 
1) To study the DCA/pyruvate binding pocket of PDHK2 using site-specific mutagenesis. 
2) To evaluate inhibition of PDHK2 activity using E1 alone as substrate. 
3) To study how K+ and Cl- ions influence PDHK2 activity. 
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4) Using Nov3r to better understand the communication between the lipoyl group binding site 
and the DCA binding site and the catalytic site. 
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Figure 1-1. Overall reaction of the pyruvate dehydrogenase complex (PDC). E1 catalyzes 
decarboxylation of pyruvate (step 1) and reductive acetylation of lipoyl groups on E2 lipoyl 
domains (lip D) (step 2). E2 catalyzes transferring of acetyl group to CoA (step 3). E3 oxidizes 
reduced dihydrolipoamide groups back to oxidized form (step 4). Re-oxidation of E3 (step 5) is 
catalyzed by E3 with reduction of NAD+. 
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Table 1-1. Components of mammalian PDC. The molecular weights, component oligomeric 
states and stoichiometries in the nature complex are given with the best estimates to date. * E2 
can form 60mer by itself but mammalian E2BP core is a 60mer with 48 E2 and 12 E3BP. 
 
Protein  Molecular weight  Component oligomeric state Stoichiometry of complex 
 
PDC reaction enzymes 
E1                  tetramer α2β2   20-30  
E1α   40,183 
E1β   30,863     
 
E2BP          48E2 + 12 E3BP 
E2   59,551    60mer * 
E3BP  48,040       
E3   50,216    dimer    12 maximal 
 
Regulatory enzymes 
PDHK1   48,391   dimer 
PDHK2   45,066   dimer 
PDHK3   45,883   dimer 
PDHK4   46,230   dimer 
 
PDHP1      αβ 
PDHP1c α  52,625 
PDHP1r β  95,656       
 
PDHP2   52,396   unknown 
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Figure 1-2. E2 and E3BP domains and their binding interactions. E2 subunit domains: L1, n-
terminal lipoyl domain; L2, inner lipoyl domain; B, E1 binding domain; I, oligomer-forming, 
acetyl-transferase catalyzing domain. E3BP domains: L3, N-terminal lipoyl domain; B’, E3 
binding domain; I’, inner domain which associates with the inner domain of E2. Dotted 
connections indicate binding interactions to kinase isoforms (PDHK1, PDHK2, PDHK3, 
PDHK4) and PDHP1. 
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Figure 1-3. Regulation of PDC reaction by reversible phosphorylation. Sign ⊕ indicates 
enhancing of the activity of regulatory enzymes. Sign ⊖ indicates that activities of regulatory 
enzymes are inhibited. Double signs imply larger effects. 
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Figure 1-4. A model for hPDHK4 gene regulation. GRE is the glucocorticoids response element 
on the hPDHK4 promoter. There are three insulin response sequences (IRS) on the hPDHK4 
promoter. A: In the presence of glucocorticoids, GRE recruits the glucocorticoids bound and 
dimerized glucocorticoids receptors (GR), which in turn bind to the P300/CBP complex (histone 
acetyltransferases). Forkhead Box factors (FOXO) also bind to IRS and P300/CBP complex. The 
whole complex interacts with transcriptional machinery to increase transcription of hPDHK4 
gene. B: In the presence of both glucocorticoids and insulin, binding of FOXO to IRS is 
disrupted. Thus transcription of hPDHK4 is decreased to normal levels. Kwon, H., et al. 
Diabetes. (2004) 53, 899-910. (67)
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Figure 1-5. Structure of Apo-PDHK2 dimer. The helix α8 (in orange color) spans the regulatory 
(R) domain. The Cross arms (360-385) are shown in yellow color. Tryptophan residues are 
shown in red color. W383 is inserted between R149 and R362 (green).
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Figure 1-6. Structure of PDHK2•ATP•DCA•Nov3r. ATP (red) binds to the catalytic (Cat) 
domain. Residues involved in K+ binding are shown in cyan. Yellow color indicates residues 
interacting between the R domain and the Cat domain (N140, Q144 from α8 of the R domain 
and S297, Y298, F296 from the Cat domain). DCA and Nov3R are shown in green. Residues 
involved in DCA site are shown in blue (R112, H115, R154, I157, R158). L160 (light sea green) 
is at the bottom of the Nov3r (also lipoyl group) binding site. W79 is shown in orange. The ions 
involved in the ATP/ADP binding are shown in purple.
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Chapter 2: Characterization of human PDHK2 
Abstract 
 Using kinetic assays, analytical ultracentrifugation (AUC) studies and fluorescence 
quenching of intrinsic tryptophan by bound ligand, the role of several residues that are located in 
the α8 helix of the R domain of PDHK2 in K+ binding, DCA/pyruvate inhibition and stimulation 
by reductive acetylation were evaluated using site-specific mutations. One of these mutants, 
L160A, was inactive. Other mutants, including double mutant R154C/L160A, were active and 
maintained the capacity to bind to L2 based on the AUC studies and activity enhancement by E2. 
Elevated K+ and Cl- reduced the specific activities of native and wild type PDHK2 with a smaller 
decrease for R158A, R154C/L160A and Q144A with or without E2. Mutation of the cross arm 
anchoring W383 caused almost two-thirds decrease of Trp fluorescence. ADP or ATP binding at 
the active site quenched the fluorescence of native kinase but not the fluorescence of W383F. 
Pyruvate also quenched the fluorescence of not only native kinase but also W383F, to a much 
less extent. Therefore, W383 provides the majority of intrinsic Trp fluorescence and its 
fluorescence is sensitive to ligand binding. 
 The Q144A mutants had very different response to K+ binding at the active site. The 
specific activity of Q144A increased 2-fold with 10 mM K+ and then decreased at higher levels 
of K+ using E1 as substrate. Based on the fluorescence quenching by ATP/ADP binding, the 
Q144A mutation caused weaker K+ binding with ATP but did not alter the weaker K+ binding 
with ADP unless Pi was included. With 100 mM K+, the Q144A mutation weakened ATP but 
not ADP binding along with a 2-fold effect of Pi in enhancing ADP binding.  
 Pyruvate or DCA weakly inhibited the specific activities of the R154C, R158A and 
R154C/L160A mutants. In AUC studies, pyruvate plus ADP caused no significant dissociation 
 23 
of GST-L2 from these mutants. The importance of both R154 and R158 was also confirmed by 
the lack of pyruvate-enhanced fluorescence quenching of the above mutants by ADP. Cl- 
inhibited the activities of R154C/L160A and R158A relatively weaker than the native kinase 
activity. Cl- also reduced the DCA or pyruvate inhibition with or without E2. All of these data 
could be fitted into a model where Cl- binds to same site as DCA/pyruvate and competes with 
them. 
 Q144 (through K+ binding) and L160 (by interaction with acetyl-lipoyl group) may play 
important roles in the signal transmission from the lipoyl group-binding site to the active site 
because Q144A and R154C/L160A (but not R154C) were less stimulated by reductive 
acetylation than the other mutants and native PDHK2. Nov3r binding at the lipoyl group binding 
site reduced but did not eliminate the inhibition of DCA/pyruvate at nearby DCA/pyruvate site 
with elevated K+ plus Pi. Nov3r appeared to not significantly affect the inhibition by Cl- at the 
same site. 
Introduction 
 PDHK2 is the most widely distributed of the four PDHK isoforms. Numerous studies 
have been done on the influence of PDHK2 activity by effectors such as pyruvate, DCA, ADP, 
K+, Cl-, Pi, NADH and acetyl-CoA (19, 21, 30, 32, 40). It has been found that PDHK2 is the 
most responsive isoform to these known effectors.  
 In a MOPS-K+ buffer containing physiological concentration of K+ and Cl-, the specific 
activity of PDHK2 is less than 10 nmol⋅min-1⋅mg-1. The activity of PDHK2 increases ~ 10-fold in 
the presence of E2 under the same conditions (32). Constructs of L1, L2 and L1-L2 have weak 
binding to the PDHK2 while dimeric construct GST-L2 binds more tightly to PDHK2 (34). 
Lipoyl domain binding alone increases PDHK2 activity less than 30%. The activity of PDHK2 
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increases only 20% when ΔBE2, in which E1 binding domain is deleted, is used (30). At the 
same time, constructs of L2-E1BD (L2 with the E1 binding domain) and L1-L2-E1BD increase 
the activity of PDHK2 almost up to the same level as in the presence of E2 (36). These data 
suggest that co-localization of PDHK2 and E1 is the major reason for PDHK2 activity increasing 
in the presence of E2. The large activity increase in the presence of E2 is the result of lipoyl 
domain-bound PDHK2 gaining access to E2-bound E1. 
Pyruvate, the substrate of the PDC reaction, is an inhibitor of PDHK2. Because pyruvate 
can serve as a substrate in E1-catalyzed reductive acetylation of lipoyl groups (TPP dependent) 
that stimulate kinase activity, the pyruvate analog, DCA, is normally used in regulatory studies 
(32). In a buffer containing K+, Cl- and Pi, PDHK2 is poorly inhibited by DCA in the absence of 
E2 while DCA strongly inhibits PDHK2 in the presence of E2. Using E1 free of TPP to prevent 
pyruvate being used in the E1 reaction, pyruvate is a stronger inhibitor of PDHK2 than DCA in 
the presence of E2 (32).  
Using 100 µM ATP, 200 µM ADP inhibits the activity of PDHK2 by 50% in the absence 
of E2 and this is not significantly changed in the presence of E2 (32). ADP binds tighter to 
PDHK2 in the presence of pyruvate/DCA while there is no significant change in ATP binding. 
On the other hand, pyruvate/DCA binding is greatly enhanced by ATP or ADP (43). Steady-state 
kinetic studies indicated that pyruvate/DCA binds efficiently to the PDHK2•ADP intermediate 
and also bind to PDHK2•ATP (40). AUC data uncover that pyruvate alone modestly weakens 
the binding of PDHK2 to lipoyl domain while ADP plus pyruvate greatly weakens the binding 
between lipoyl domain and PDHK2 (43). Thus, pyruvate/DCA inhibition is in part a result of the 
dissociation of lipoyl domain from PDHK2, which decreases the access of PDHK2 to substrate 
E2-bound E1. 
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Through reaction with increasing NADH:NAD+ and acetyl-CoA:CoA ratios, oxidized 
lipoyl groups are converted to reduced and acetylated forms which stimulate PDHK2 activity. 
Stimulation of PDHK2 activity by reductive acetylation can only be observed in buffers 
containing elevated K+, Cl- and / or Pi (32, 40). Reduction of lipoyl domain alone gives ~ 1.6-
fold increase in PDHK2 activity; acetylation of E2 increases PDHK2 activity up to 3.5-fold from 
the initial activity without effectors (32). E2ox in which most lipoyl groups are in the oxidized 
state greatly decreases the capacity of E2 to stimulate PDHK2 activity (40). It is found that GST-
L2red with reduced lipoyl groups binds PDHK2 more than 7-fold tighter than GST-L2 with 
oxidized lipoyl groups (34). While the extent of binding of PDHK2 to E2ox is not significantly 
decreased from that with untreated E2, reduction of lipoyl group of E2ox with NADH:NAD+ or 
DTT increased the binding of PDHK2 to E2 60mer (40). 
An ordered mechanism in which ATP binds first and the dissociation of ADP as rate 
limiting step is proposed for PDHK2 in the presence of E2 with no stimulatory effectors (30, 40). 
Reductive acetylation of lipoyl group increases Vmax and the Km for ATP of PDHK2 while Km 
for ATP decreases in the presence of E2ox (40).  
The PDHK inhibitor Nov3r does not prevent the binding of ATP at the active site of 
PDHK. Nov3r class compounds do not inhibit the phosphorylation of peptide substrate (83). 
Nov3r inhibits E2-enhanced PDHK2 activity and but only slightly inhibits the phosphorylation 
of free E1. Nov3r appears to be an analog of acetyl-dihydrolipoyl-lysine (86). Crystal structures 
revealed that Nov3r and the lipoyl prosthetic group of L2 bind to PDHK2 at the same site. The 
mechanism for Nov3r inhibition is to prevent the binding of lipoyl domain to PDHK2 by 
preventing the binding of L2’s lipoyl group. 
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Previous studies indicate that elevated K+ and Pi significantly altered the capacity of 
effectors to influence PDHK2 activity (32). Elevated K+ lowers the Km for ATP with an 
equivalent decrease in kcat and causes stronger inhibition by ADP and DCA (40, 80). 
The crystal structure of Apo-PDHK2 dimer reveals a cross arm structure that is formed 
by the C-terminal tail (residues 365-384) from both subunits that is anchored by Trp383 and 
Cys384 (Fig. 1-6) (76). A similar cross arm has also been found in the PDHK3•L2 structure. The 
cross arm interacts with L2 (77). This cross arm is not resolved in the crystal structure of rat 
PDHK2•ADP (74) and human PDHK2•ADP•DCA, suggesting that cross arm might change 
with the binding of ADP and DCA. An AUC study found that pyruvate plus ADP resulted in 
formation of PDHK2 tetramer (43). There are three tryptophan residues in PDHK2. Apart from 
Trp383, Trp371 is also located in the cross arm and is exposed to the solvent. Trp fluorescence 
(especially of Trp383) can be a good indicator of cross arm change with ligand binding because 
Trp fluorescence is sensitive to changes in the surrounding electrostatic environment (81, 82). 
The catalytic site, DCA binding site, lipoyl domain and lysine-lipoyl group (also Nov3r) 
binding site, and K+ binding site are identified or suggested from the crystal structures of human 
PDHK2 (76) and PDHK3 (77) (Fig. 1-6). The ATP/ADP binding site (catalytic site) is located in 
the Cat domain with several conserved residues and sequence segments (termed boxes) that bind 
to adenine, phosphate groups and also Mg2+ (see above). Based on the crystal structure of 
PDHK3 and related BCDK, a K+ ion is proposed to bind at the active site (76). The backbone 
carbonyl groups of Leu 295, Ser297, Gly319 and hydroxyl group of Ser301 were modeled to 
chelate K+ ion along with α-phosphate of ATP or ADP. Gln144 from the N-terminus of α8 
forms hydrogen bonds with Phe296 and Tyr298 in the Cat domain. There is also a hydrogen 
bond between Asn140 from α8 and Ser297 in the Cat domain. These interactions may connect 
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helix α8 of the R domain to bound K+ and therefore to the ATP/ADP binding site in the Cat 
domain.  
Based on the crystal structure of human PDHK2, the binding site for Nov3r is located at 
the end of the R domain at a position far from the ATP binding site (Fig. 1-6) (76). It is the same 
site that binds lipoyl prosthetic group based on the crystal structure of PDHK3•L2 (77). The 
lipoyl group binding site of PDHK2 is a hydrophobic cylindrical pocket formed by residues 
Leu23, Phe28, Phe31, Phe44, Leu45, Leu160, Ile167, Phe168 on helices α2/α3/α8 and other 
residues which are conserved in other PDHK isoforms. Based on the crystal structure of 
PDHK2•ATP•Nov3r (76), Leu160 is positioned next to where the CH3 group of acetyl-
dihydrolipoylamide is predicted to interact in this site. This residue may play important role in 
the stimulation of PDHK2 activity by reductive acetylation. 
The DCA/pyruvate site is located in the center of the R domain with the entry facing the 
extended groove of the active site cavity formed between the R and the Cat domains with 
conserved arginine residues Arg154 and Arg158 (Fig. 1-6) (76). The other residues forming the 
binding pocket are Leu53, Tyr80, Ilelll, His 115, Ser153, Ile157, and Ile161 in PDHK2. The 
carboxyl group of bound DCA appears to form an electrostatic interaction with Arg154 and may 
also interact with R158 and His115. Arg158 appears to block the entry to the DCA site in the 
structure with DCA bound. These residues involved in the DCA binding are highly conserved in 
the PDHK family with the exception of PDHK3, in which Ile157 is replaced by Phe. This 
replacement may be the reason for weak DCA/pyruvate inhibition of PDHK3.   
From above introduction, helix α8 connects the catalytic site, the DCA site and the lipoyl 
group binding site (Nov3r site). It may play important role in the communicating effects between 
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these sites. To understand the communication, site-specific mutagenesis was used to test the 
importance of specific residues on helix α8.  
Materials and Methods 
Materials 
 Recombinant human E1, E2 and E3 were prepared as previous reported (32). Using KOD 
Hot Start DNA polymerase (Novagen), mutagenesis was conducted on human PDHK2 using a 
two-step PCR procedure. The primers used for mutation were listed in Table 2-1.  T7 and T3 
primers were sequencing primers that flank the cDNA of human PDHK2 in the vector PET28a 
(Novagen). The forward and reverse primers for specific mutants had a complementary 
sequence. In the first-step PCR, T7 and T3 were coupled separately with reverse and forward 
primers for specific targeted residues to get the cDNA segments encoding the N-terminal part 
and C-terminal part of mutant PDHK2. The cDNA fragments from first PCR were purified for 
using in the second PCR. In the second step, products of the first-step PCR denatured, annealed 
using the complementary bases and then extended using each other as template to get a full-
length cDNA for individual mutant. The whole full-length mutated cDNA was then amplified by 
PCR using T7 and T3 as primers also in the second PCR (Fig. 2-1). The amplification cycle was 
set as following for PCR of both steps: 
 Initial denature: 95 °C, 10 min. 
 Elongation cycles: 95 °C, 25 s; 50 °C, 25 s; 70 °C, 40 s. Total 25 cycles 
 Final extension: 70 °C, 10 min. 
 The final products were purified and cut by restriction enzymes XbaI and HindIII (New 
England Biolabs) and inserted into expression PET28a plasmids (Novagen) treated with the same 
restriction enzymes. The introduction of each mutation was confirmed by sequencing.  
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Table 2-1. Primers used for site-specific mutagenesis. T7 and T3 are vector sequences flanking 
hPDHK2 cDNA in previous PDHK2 vector (32). Mutant-introducing bases are in bold. 
 
T7: TAATACGACTCACTATAGGG 
T3: GCTAGTTATTGCTCAGCGG 
Q144A:  
 Forward: CCAGAACATCGCGTACTTCC 
 Reverse:  GGAAGTACGCGATGTTCTGG 
I157F:  
 Forward: GCATCTCCTTCCGCATG 
 Reverse:  CATGCGGAAGGAGATGC 
R154C:  
 Forward: CTACCTCAGCTGCATCTCCATC 
 Reverse: GATGGAGATGCAGCTGAGGTAG 
L160A:  
 Forward: GCATCTCCATCCGCATGGCCATCAACCAGCACACC 
 Reverse:  GGTGTGCTGGTTGATGGCCATGCGGATGGAGATGC 
R158A: 
 Forward: GCCGCATCTCCATCGCCATGCTCATCAACCAGC 
 Reverse:  GCTGGTTGATGAGCATGGCGATGGAGATGCGGC 
W383F:  
 Forward: GGCCGGCGACTTCTGTGTGCCCAG 
 Reverse:  CTGGGCACACAGAAGTCGCCGGCC 
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Figure 2-1. Procedures for site-specific mutagenesis. In the first step, Primers T7 and T3 were 
coupled with reverse or forward primers of specific mutant separately to produce fragments of 
PDHK2 DNA with specific mutation. The products were purified and used in the second step. In 
the second step, the DNA fragments were denatured, annealed using the complementary 
sequence and then extended to get the whole mutated DNA.  Finally, the mutated DNA was 
amplified using T7 and T3 as primers. The final PCR products were purified and cut with 
restriction enzymes XbaI and HindIII to be inserted into PET28a plasmids. The open circles 
represent the bases mutated. The restriction sites for XbaI and HindIII are marked respectively 
with open or closed triangles. 
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 All expressed PDHK2 mutants had a His-tag and a PreScission protease site at their N-
terminus. [γ-32P]ATP was from Dupont NEN. Pyruvate, DCA, NADH, NAD, Coenzyme A, and 
acetyl-CoA were from Sigma Chemical Co. 
Expression and purification of PDHK2 mutant proteins 
 To express and purify the PDHK2 mutant proteins, a general procedure developed for 
wild type PDHK2 (43) were used. Plasmid of specific PDHK2 mutant was co-transformed along 
with a plasmid encoding GroEL and GroES (Dupont) into competent E. coli BL21(DE3). 
Selection for the presence of both plasmids was done on LB plates containing 50 µg/ml 
kanamycin and 50 µg/ml chloramphenicol. PDHK plasmid-containing bacteria were grown at 
37 °C to mid-log phase (A600 0.6) in LB media containing 50 µg/ml kanamycin and 50 µg/ml 
chloramphenicol. 0.5 mM isopropyl--D-thiogalactopyranoside (IPTG) was added to induce the 
expression at room temperature (22-24 °C) for 16 h. Bacteria were harvested by centrifugation at 
4,000 × g for 20 min at 4 °C. The bacterial pellets were resuspended to 10% (w/v) in HN buffer 
(20 mM Hepes-Na buffer, pH 8.0, 0.5 M NaCl, 1% (v/v) ethylene glycol). Ice water-cooled 
suspensions were sonicated by six repetitions of 50% pulsing at 250 watts for 30 s followed by at 
least 1 min of cooling. Supernatants were cleared by centrifugation at 10,000 × g for 20 min at 
4 °C. Pluronic-F68 and imidazole were added to the supernatant to a level of 0.1% (w/v) and 5 
mM separately. The supernatant was loaded into column filled with 1-2 ml of equilibrated 
TALON resin (CLONTECH) that was balanced with HN buffer at 4 °C. The gel resin was 
washed with HN buffer containing 0.1% Pluronic F68 and 5 mM imidazole until the absorbance 
of flow through was lower than 0.2 at 280 nm. The resin was then washed with HN buffer 
containing 0.1% Pluronic F68 and 15 mM imidazole until the absorbance of flow through was 
lower than 0.2 at 280 nm. HG buffer (20 mM Hepes-Na, pH 8.0, 0.5 M NaCl, 1% (v/v) ethylene 
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glycol, 10% (v/v) glycerol, 0.1% (m/v) Pluronic F-68) containing 100 mM imidazole was used to 
elute PDHK2 protein. 1 mM dithiothreitol, 1 mM EDTA, and 100 units of PreScission protease 
(Amersham Pharmacia Biotech) were added into PDHK2 protein fractions pool for a 1- or 3-h 
incubation on ice. Following PreScission protease digestion, protease was removed by passing 
the mixture through a column with 0.25 ml of GSH-Sepharose (Amersham Pharmacia Biotech) 
equilibrated with HG buffer. PDHK2 preparations were desalted on a Sephadex G-25 column 
equilibrated with Hepes-Na buffer (20 mM, pH 8.0, 0.5 mM EDTA, 0.1% (m/v) pluronic F-68, 
10% (v/v) glycerol, 1% (v/v) ethylene glycol and 100 mM NaCl). The purified PDHK2 mutants’ 
protein were more than 90% pure based on the SDS-PAGE analysis. PDHK2 preparations were 
stored unfrozen at 20 °C. Final PDHK2 recovery was typically 5-10 mg per liter of bacterial 
growth media for PDK2. For L160A, I157F and W383F mutants, the recovery was around 1-3 
mg per liter of bacterial growth media. 
PDHK2 activity assays 
 PDHK2 activity assays were measured in duplicate as the initial rate of incorporation of 
32P-phosphate from [γ-32P]ATP into E1 at 30°C. In 25 µl assay system, 10 µg E1 was used for 
each assay. For measuring E2-activated PDHK2 activity, 10 µg E2 was included, resulting in all 
E1 being bound to E2 (~ 24 E1 tetramer/E2 60mer). The kinase concentration was ~ 0.1 µg/assay 
or ~ 0.02 µg/assay depending on E1 or E1•E2 was used as substrate. The ATP concentration 
used was 100 µM unless stated otherwise. The standard buffer system used was 50 mM Hepes-
Tris, pH 7.6, 0.1% Pluronics F68, 2 mM DTT, 2 mM MgCl2, 0.5 mM EDTA (Low salt buffer). 
K+ (balanced with Hepes), Cl- (balanced with Tris) and Pi (balanced with Tris) were additionally 
added to specific levels in some experiments. In most assays, ~ 8 mM potassium phosphate was 
introduced with E1 that was stored in 50 mM potassium phosphate buffer, pH 7.5, containing 1.0 
 33 
mM DTT and 0.5 mM EDTA. E1 precipitated in other buffers tested. In studies that evaluated 
the influence of specific ions on PDHK activity, concentrated E1 (more than 8.0 mg/ml in 10 
mM potassium phosphate buffer) was used. Using this concentrated E1, the initial potassium 
phosphate concentration was reduced to ~ 0.5 mM.  
When E1•E2 was used as substrate, E1, E2 and kinase were mixed and pre-incubated on 
ice for 1-2 hr prior to assay. When E1 alone was used as substrate, kinase was added into E1 first 
before the assays. In general, diluted PDHK2 (less than 0.01 g/l) was stable within 0.5 hr. 
Reaction mixtures (kinase, substrate and buffer) were incubated 1 min at 30°C. ATP was added 
to initiate the kinase reaction for 1 or 2 min. Reactions were terminated by spotting to dry 
Whatmann 3MM filter paper (Millipore Co.) discs pre-soaked with 10% trichloroacetic acid 
(TCA) solution. The discs were washed five times with 10% TCA to remove unbounded 
radioactive ATP. TCA was removed by washing the discs with ethanol and ethyl ether. The disks 
were dried and counted using Beckman LS 6500 multi-purpose scintillation counter. 
Regulatory assays 
 In the assays evaluating DCA or pyruvate inhibition, DCA or pyruvate was added 1 min 
before ATP. Nov3r (in DMSO) was also added 1 min before ATP (final concentration of DMSO 
was 2%). Stimulation assays were performed using a buffer containing 50 mM Hepes-Tris, pH 
7.6, 0.1% Pluronics F68, 2 mM MgCl2, 0.5 mM EDTA, 90 mM K+, 60 mM Cl- and 20 mM Pi. 
NADH and NAD+ were added at a 3:1 ratio (0.6 mM/0.2 mM) 60 s and 50 µM acetyl-CoA, 
when included, was added 20 s before ATP in the presence of NADH and NAD+. When 
NADH/NAD+ and acetyl-CoA were used, 2 µM E3 was included to catalyze the reversible 
reduction of lipoyl groups on E2. 
Circular dichroism (CD) 
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 Circular dichroism spectra were collected for all mutants and wild type PDHK2 using a 
quartz cell with a 1 mm light path in 20 mM potassium phosphate (pH 7.5) including 0.5 mM 
EDTA at 20°C. Using a Jasco J720 spectrometer at least 16 scans were averaged with each 
accumulated at 50 nm/min. Spectra were collected from 190 nm to 260 nm at a kinase 
concentration of 0.2 mg/ml. Protein concentrations were based on the Pierce BCA (bicinchoninic 
acid) Protein Assays. The instrument was calibrated using D-10-camphorsulfonic acid as a 
standard. 
Fluorescence quenching 
 Steady-state fluorescence spectra were recorded with a Cary Eclipse fluorescence 
spectrophotometer (Varian, Inc.) at 25°C in 50 mM potassium phosphate buffer, pH7.5, 
containing 0.5 mM EDTA and 2.0 mM MgCl2. Fluorescence spectra of wild type and mutant 
PDHK2 were recorded from 320 nm to 420 nm (with 5 or 2.5 nm slit) with exitation at 290 nm 
(with 10 nm or 5 nm slit). Standard quartz (1X1 cm) cuvette and 2.0 ml initial volume were used. 
The concentration of kinase was continuously corrected for the dilution due to addition of 
concentrated ligand during the titration of PDHK2 by ligands. Although spectra from 320nm to 
420 nm were recorded, the corrected fluorescence change at 350 nm was used to assess 
fluorescence quenching with the change of the varied ligand. Kinase concentration was ~ 0.5 
µM. The calculation of half quenching (L0.5) was done as previous described (43). 
Sedimentation velocity analysis 
 Sedimentation velocity experiments were conducted as previously described using an 
Optima XL-I ultracentrifuge (11, 23, 34). The buffer used was 50 mM potassium phosphate 
buffer, pH 7.5, containing 0.5 mM EDTA and 2.0 mM MgCl2. 3.7 µM PDHK2 and 7.5 µM 
GST-L2 were used unless specified. When indicated, ATP, ADP, pyruvate, or combinations of 
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pyruvate and ATP or ADP were added at the indicated concentrations. Sedimentation was 
conducted at 20 °C and the profiles were recorded at 280 nm using double sector cells at a speed 
of 49,000 rpm and 5 min intervals. Sedimentation data were analyzed with DCDT+ software 
(version 1.6).  
Results 
CD and fluorescence spectra of wild type PDHK2 and mutants 
 The mutants PDHK2 made were Q144A, R154C, I157F, R158A, L160A, R154C/L160A 
and W383F. The successful mutations were confirmed by DNA sequencing. The mutant proteins 
were expressed and purified as described previously for wild type PDHK2 (32). There were no 
significant differences in the yield of soluble mutant and the wild type kinase proteins. 
 Using a 1 mm cuvette, the CD spectra of wild type and mutant PDHK2 were measured in 
50 mM potassium phosphate buffer, pH 7.5, containing 0.5 mM EDTA and 2.0 mM MgCl2 (Fig. 
2-2). The CD spectra of wild type PDHK2 had two peaks at 208 nm and 220 nm, an indication 
that α helices dominated the secondary structure. All mutants apart from L160A had CD spectra 
similar to wild type PDHK2, indicating that they had secondary structure similar to wild type 
PDHK2. The CD spectrum of L160A had both peaks but was significantly different from that of 
wild type PDHK2 and other mutants. This indicated that there were some changes in the 
secondary structure of L160A. 
 There are three tryptophan residues in PDHK2. Fig. 2-3 shows the emission spectra of 
wild type PDHK2 and several mutants. The fluorescence spectra were measured from 320 nm to 
420 nm with excitation at 295 nm in phosphate buffer. At this excitation wavelength, most of 
fluorescence comes from tryptophan residues (81, 82). Wild type PDHK2 had a broad emission 
(EM) peak with a maximum at 352 nm. The fluorescence spectra of R154C and R154C/L160A  
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Figure 2-2. Circular dichroism patterns for wild type and mutated PDHK2. Using a 1 mm 
cuvette, the CD spectra of wild type and mutated PDHK2 were measured using a Jasco J720 
spectrometer at room temperature (22 °C). Spectra were collected from 260 nm to 190 nm using 
2.16 µM kinase dimer with the exception of 0.3 µM W383F. (Data were collected by Dr. 
Hiromasa, Y. The first panel was published in J. Biol. Chem, (2006) 281, 12568-12579 (43)). 
Published data were reproduced with permission as covered under the general Copyright 
Permission Policy of J. Biol. Chem. 
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Figure 2-3. Fluorescence emission spectra of wild type and mutated PDHK2.  Fluorescence 
spectra of 0.5 µM native and mutated PDHK2 were collected from 320 nm to 420 nm with 
excitation at 290 nm. (Data were collected by Dr. Hiromasa, Y.) 
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matched very well with wild type PDHK2. Q144A and I157F had the same EM peak maximum 
(352nm) as wild type PDHK2 but lower fluorescence intensities (~ 85% of wild type). L160A 
had a significantly different fluorescence emission spectrum. The EM peak of L160A was at 346 
nm, a 6 nm blue shift comparing with the EM peak of wild type PDHK2. At the same time, the 
maximum fluorescence intensity was 30% lower than the maximum fluorescence intensity of the 
wild type kinase. The difference in the fluorescence emission spectra again suggests that the 
L160A mutant has a different conformation from wild type PDHK2 and other mutants. As a 
result, L160A was not active (below). 
Kinase activities of mutants 
 L160A had no activity in several preparations, in agreement with the above CD and 
fluorescence results indicating this mutant had a different conformation from the wild type 
kinase.  Other mutants of PDHK2 maintained the ability to phosphorylate E1. Table 2-2 shows 
the specific activities of these mutants in low salt buffer and high salt buffer (same as low salt 
buffer with additional 90 mM K+ and 60 mM Cl-) using E1 or E1•E2 as substrate. All assays (25 
µl) were conducted in the presence of 100 µM ATP with 10 µg E1 (2.63 µM) in absence or 
presence of 10 µg E2 (0.11 µM 60mer)*.  
Using E1 alone as substrate, I157F and R154C/L160A displayed activities comparable to 
wild type PDHK2 in a low salt buffer. The R154C mutant had the lowest activity that was only 
11% of the activity of wild type PDHK2. Q144A had the highest activity that was 2.2-fold higher 
* It should be noted that, without E2, this level of E1 is well below the Km of wild type PDHK2 
for E1 and that, with E2, adding additional E1 does not significantly increase the observed rates 
with wild type PDHK2 (40). Therefore, much of the observed activity increase with inclusion E2 
is due to a change in availability of E1 as described in the general introduction. In the high salt 
buffers, 100 µM ATP is well above the Km of PDHK2 for ATP in the absence of E2 and 
somewhat above the Km for ATP with E2 (40). The Km of wild type PDHK2 using the low salt 
buffers is not established. Fig. 2-8 below varied ATP at one E1 level in the absence of E2, but 
the apparent Km for ATP derived could be very different from the true Km for ATP. 
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Table 2-2. Specific activities of wild type and mutant PDHK2. Kinase assays were conducted 
with 100 µM ATP at 30 °C in the presence or absence of E2 with the indicated buffer. Low salt 
buffer: 50 mM Hepes-Tris, pH7.6, 0.5 mM EDTA, 0.1% pluronic F-68, 2 mM MgCl2, 2 mM 
DTT. High salt buffer: same as low salt buffer with additional 90 mM K+ and 60 mM Cl-. 
Around 10 mM or 12 mM KxPO4 was introduced by E1 or E1•E2. The kinase concentration was 
8.8 nM in assays conducted in the presence of E2 and 44 nM in assays conducted in the absence 
of E2.  
 
 
  
Low salt High salt 
  - E2  + E2  - E2  + E2 
 
 nmol·min
-1
.mg
-1
  
Wild type 106±8 715±6 9.5±0.5 172±4 
R154C 12.1±0.5 421±3 3.1±1.3 167±3 
R158A 29.7±0.9 393±2 5.8±0.2 157±9 
R154C/L160A 77.6±0.3 481±9 25.7±0.3 225±17 
I157F 81.2±0.5 647±5 4.8±1.0 73.5±3.4 
W383F 53.4±0.1 579±27 4.1±0.1 113±3 
Q144A 232±4 908±14 51.2±0.2 383±3 
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than the wild type kinase. The activities of R158A and W383F were somewhat lower than that of 
wild type PDHK2 under the same conditions. High salt, 90 mM K+ and 60 mM Cl- (near 
physiological levels), reduced the activity of kinase with E1 alone as substrate. The activity 
reductions varied from > 11-fold for wild type, I157A and W383F mutants to less than 5-fold for 
R154C, R158A, R154C/L160A and Q144A mutants. The different activity reduction due to 
elevated ions may be a reflection of the specific roles of mutated residues or be a result of 
changed stability in these PDHK2 constructs. As a result of different responses to an elevated 
level of ions, R154C/L160A and Q144A mutants had 2.7-fold and 5.4-fold higher specific 
activities than wild type PDHK2 with E1 as substrate in high salt buffers. Thus, the 
R154C/L160A dual mutant changed from less active to more active than wild type PDHK2 with 
the transition from a low salt buffer to a high salt buffer. At the same time, the Q144A mutant 
was 4-fold active than wild type PDHK2 in high salt buffer as it was less influenced by salt.  
The activities of PDHK2 mutants were also assessed in the presence of E2 (Table 2-2). 
Using E1•E2 as substrate, all PDHK2 mutants had activities higher than using E1 alone as 
substrate in both buffers, indicating that these mutants maintained the capability of binding to the 
lipoyl groups in E2. The activity enhancement by E2 varied among mutants and was influenced 
by the ions levels in the buffer. E2 caused large activity increases for all kinases in a high salt 
buffer than in a low salt buffer. Under low salt conditions, the specific activity of native PDHK2 
was increased around 7-fold by E2. While the activity of wild type PDHK2 was increase more 
than 18-fold by E2 in a high salt buffer. The R154C mutant, who had the lowest activity using 
E1 alone as substrate, underwent the largest activity increase by E2. E2 caused the lowest 
activity increase for Q144A, which had the highest activity using E1 alone as substrate.  
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In the presence of E2, elevated ions also decreased the specific activity of PDHK2 (wild 
type and mutants), but less of a decrease than in the absence of E2 (Table 2-2). These data 
suggested that lipoyl domain binding might stabilize PDHK2. Comparing with the wild type 
PDHK2, I157F and W383F, the activities of R154C, R158A, R154C/L160A and Q144A mutants 
again were reduced less by elevated salt even using E1•E2 as substrate. Therefore, these 
mutations (R154C, R158A, R154C/L160A, Q144A) might alter how ions affected PDHK2 
activity. 
As a result of unequal activity enhancement by E2 and different activity reduction by 
elevated salt, the activities of R154C and R158A changed from more than 70% lower than wild 
type PDHK2 in the low salt buffer using E1 as substrate to almost equal to the native kinase in 
the high salt buffer using E1•E2 as substrate (Table 2-2). Using E1•E2 as substrate in a high salt 
buffer, I157F had an activity similar to that under low salt conditions using E1 as substrate. 
Under these conditions, Q144A maintained the highest specific activity.  
Based on above specific activity assays for the mutants, it was found that L160A was 
inactive as it had a conformation different from wild type PDHK2. All other mutants (R154C, 
R158A, R154C/L160A, I157F, W383F and Q144A) were active. These mutants maintained the 
capacity to bind to and be activated by E2. Elevated salt (K+ plus Cl-) reduced the activities of 
the wild type and mutants PDHK2.  Binding of E2 to kinase appeared to stabilize the enzyme, 
reducing but not eliminating the influence of high salt. The activities of R154C, R158A, 
R154C/L60A and Q144A mutants were decreased less by high salt than wild type PDHK2. The 
reasons for such weaker ion effects would be discussed below. 
Fluorescence of W383F 
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There are three tryptophan residues in human PDHK2: Trp79, Trp371 and Trp383 (see 
Fig. 1-5 and 1-6). Trp79 is located in helix α5 of the R domain of PDHK2. Trp371 and Trp383 
are located in the cross arms. Trp371 is in the middle of the cross arm and is partially exposed to 
solvent. Trp383 is at the end of the cross arm, inserted between Arg362 and Arg149 of the other 
subunit at the interface of the R-Cat domain (76). Trp383 interacts with other residues from the 
other subunit (Leu152, Leu363 and Pro364). As noted in the introduction of part I, the cross arm 
was not observed in the crystal structure of rat PDHK2•ADP (74) and human 
PDHK2•ADP•DCA (76). Under those conditions, Trp371 or Trp383 are probably exposed to 
different environments, resulting in changes in their fluorescence. However, even small 
conformational changes can alter the electrostatic environment around Trp383, to thereby cause 
changes in fluorescence. Phe was used to replace Trp383, hoping the replacement would not 
significantly alter the PDHK2 structure, the cross arm would be maintained, and only the 
fluorescence of the kinase would be altered. 
There was a large difference between the emission spectrum of W383F and wild type 
PDHK2 (Fig. 2-4). The fluorescence EM peak of W383F was at 342 nm, a 10 nm blue-shift from 
the 352 nm of wild type. The fluorescence intensity at 350 nm was decreased by 60%. These 
results indicated that Trp383 provided the major part of tryptophan fluorescence in PDHK2. 
Trp79 could be another contributor to total fluorescence and would be expected to have an EM 
peak at shorter wavelength as it is mostly buried with generally hydrophobic groups surrounding 
it. Trp371 is expected to contribute minimally to fluorescence because it was substantially 
exposed to solvent (81). When Trp383 was replaced by phenylalanine, it is likely that the 
majority of the residual tryptophan fluorescence is from W79.  
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Figure 2-4. Fluorescence emission spectra of wild type PDHK2 and W383F.  Fluorescence 
spectra of 0.7 µM native and mutated PDHK2 were collected from 320 nm to 420 nm when 
exited at 290 nm. The difference between the fluorescence spectra of wild type PDHK2 and 
W383F was shown in ο-curve. (Data were collected by Dr. Hiromasa, Y. and published in J. 
Biol. Chem, (2006) 281, 12568-12579 (43)). Published data were reproduced with permission as 
covered under the general Copyright Permission Policy of J. Biol. Chem.
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 In the potassium phosphate buffer, the Km for ATP of W383F was 35±7 µM, which was 
close to the Km of wild type PDHK2. But W383F had a Vmax 30% lower than wild type using 
E1•E2 as substrate (Fig. 2-5). Therefore, the W383F mutant maintained the ability not only to 
interact with substrates (E1 and ATP) but also to bind to lipoyl domain of E2. Combined with 
above information from the CD spectra and activity assays, these results demonstrated that the 
replacement of W383 with Phe did not significantly alter the structure of PDHK2.  
Fluorescence quenching 
Fig. 2-6A shows how ADP and ATP influenced the tryptophan fluorescence spectrum of 
PDHK2. In the potassium phosphate buffer, 150 µM ADP caused the fluorescence intensity at 
350 nm to be decreased by 45%, while 150 µM ATP caused a decrease of 53%. ADP and ATP 
also caused a blue-shift of fluorescence EM peak. Mg2+ was required for ADP and ATP binding 
to PDHK2. PDHK2 has no activity in the absence of Mg2+. There was no change in the 
fluorescence spectra of PDHK2 in the presence of either ADP or ATP (less than 1.0 mM) when 
there was no Mg2+ (data not shown). Therefore, the observed fluorescence quenching was due to 
specific binding of nucleotides as a Mg2+ complex to PDHK2.  
Fig. 2-6B and 2-6C show the change of fluorescence intensity at 350 nm with the 
increasing of ADP or ATP concentration. Fluorescence quenching of PDHK2 by nucleotide was 
fit by a simple equilibrium binding at a single class of sites as described in previous studies (30, 
40). The estimated maximum quenching by ATP was 53.5 ± 1.5% and ADP had maximal 
quenching of 48.8 ± 2.5%. ATP underwent half-maximal quenching at a concentration (L0.5) of 
2.8 ± 0.3 µM. The L0.5 for ADP of PDHK2 was 15.3 ± 1.5 µM. The estimated L0.5 for ATP was 
close to the Kd determined in other studies (30, 40).  
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Figure 2-5. Double reciprocal plot showing the variation in the activities of W383F and wild type 
PDHK2 with the ATP concentration. Assays were conducted in a potassium phosphate buffer 
with additional 90 mM K+ and 60 mM Cl-. The concentrations of PDHK2 dimer, E1 and E2 were 
41 nM, 2.6 µM and 0.11 µM (60mer) respectively. 
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Figure 2-6. Quenching of the intrinsic fluorescence of wild type PDHK2 and W383F by ATP or 
ADP. All data were obtained in 50 mM potassium phosphate buffer (pH7.6) with excitation at 
290 nm. A, Influence of ATP or ADP on fluorescence spectra of native PDHK2. B and C, 
Fluorescence quenching at 350 nm of wild type PDHK2 (open circle) and W383F (closed circle) 
by ATP (B) or ADP (C). 100 µM pyruvate was added to the mixture after the highest level of 
ATP or ADP (arrow). (Data were collected by Dr. Hiromasa, Y. and published in J. Biol. Chem, 
(2006) 281, 12568-12579 (43)). Published data were reproduced with permission as covered 
under the general Copyright Permission Policy of J. Biol. Chem. 
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As shown in Fig. 2-4, W383 provides most of the tryptophan fluorescence of PDHK2. To 
evaluate the role of W383 in fluorescence quenching by nucleotide, quenching of fluorescence of 
wild type and W383F PDHK2 were compared. Contrary to wild type PDHK2, ATP or ADP 
caused no fluorescence quenching of W833F (Fig. 2-6B and 2-6C). These results indicate that 
fluorescence quenching of wild type PDHK2 by ADP or ATP resulted mainly from the changes 
in W383 fluorescence. Nucleotide binding at the active site must introduce changes in the 
electronic environment around Trp383 on the cross-arm to lower the fluorescence intensity.  
Pyruvate caused fluorescence quenching of wild type PDHK2 with a L0.5 of 590 ± 60 µM 
(Fig. 2-7). These data indicate that pyruvate could bind to free PDHK2. Pyruvate also caused a 
fluorescence quenching in W383F (Fig. 2-7). In the presence of 105 µM ATP or 175 µM ADP, 
fluorescence quenching of wild type PDHK2 by nucleotide almost reached the maximum. 
Addition of 100 µM pyruvate caused further fluorescence quenching of wild type PDHK2 (Fig. 
2-6B and 2-6C). Under the same condition, addition of pyruvate also caused fluorescence 
quenching of W383F. But the further quenching of W383F mutant was significantly less than 
that of the wild type kinase (Fig. 2-6B, 2-6C). Pyruvate inhibition studies (below) confirmed that 
W383F maintained the capability of binding to pyruvate. These results indicate that binding of 
pyruvate introduced changes not only in the electronic environment around W383 and but also 
around at least one other tryptophan residue. 
 From the studies of the W383F mutant, it could be concluded that the cross arm 
anchoring W383 provides the majority of intrinsic Trp fluorescence of PDHK2. Nucleotide 
binding to the active site caused mostly the fluorescence quenching of W383. While pyruvate 
binding to the DCA/pyruvate site resulted in not only the fluorescence quenching of W383 but  
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Figure 2-7. Fluorescence quenching of wild type PDHK2 and W383F by pyruvate. All data were 
obtained at 350 nm in 50 mM potassium phosphate buffer (pH 7.6) when excited at 290 nm 
using 0.7 µM PDHK2 dimer. (Data were collected by Dr. Hiromasa, Y.).  
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also other tryptophan residue (see discussion). The intrinsic Trp fluorescence quenching was 
used to evaluate the binding of ligand (43). 
PDHK2 activity using E1 as substrate 
There was much evidence that PDHK2 activity was influenced by ions. The combination 
of elevated levels of Cl-, K+ and Pi reduced the activity of PDHK2 in the presence of E2 (30, 32). 
PDHK2 was more active in the presence of low levels ions such as K+, Cl- and Pi than with 
elevated ion levels in the presence of E2 (30, 32, 40). From above activity assays, it was found 
that E2 stabilized and made PDHK2 less affected by K+ and Cl-. Most reports about the 
functional regulation of PDHK2 activity have used E1•E2 as substrate, as E2 enhanced the 
activity of PDHK2 and the activity of PDHK2 was relatively low under high salt conditions (32, 
36, 85). To exclude the influence of E2, E1 alone was used as substrate in some studies in this 
thesis.  
The kinetic basis for the change of the specific activities of human PDHK2 with salt 
levels was partially evaluated using 2.6 µM E1 alone as substrate with the ATP concentration 
varied from 10 µM to 400 µM (Fig. 2-8).  The native PDHK2 had an apparent Km for ATP of ~ 
23 µM and an apparent Vmax of ~ 139 nmol⋅min-1·mg-1 with low salt buffer containing 10 mM 
KxPO4 from E1 source. With the addition of extra 90 mM K+ and 20 mM Pi, the apparent Km for 
ATP was decreased by 4-fold to ~ 6.4 µM, and the apparent Vmax was decreased 2.7-fold to ~ 49 
nmol⋅min-1·mg-1. The reduction of both the Vmax and the Km for ATP by elevated ions using E1 
alone as substrate was very similar to previous studies using E1•E2 as substrate (40). These data 
suggest that elevated ions increase the affinity of binding adenine nucleotide at the active site 
and the tighter binding reduces the reaction speed even when E1 is the substrate. These results 
are consistent with an ordered mechanism in which ADP dissociation remains (as with E1•E2) 
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Figure 2-8. Double reciprocal plot of the variation in initial velocity of wild type PDHK2 with 
ATP in different buffers. Data shown by open circles were obtained in buffer A: 50 mM Hepes-
Tris, pH 7.6, 0.5 mM EDTA, 0.1% pluronic F-68, 2 mM MgCl2, 2 mM DTT. Data shown by 
closed circles were obtained in Buffer B (Same as Buffer A but also containing additional 90 
mM K+ and 20 mM Pi). Around 10 mM KxPO4 was also introduced with E1. 
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a slow step even with E1 being used as a substrate at a level well below the Km for E1. 
Mutant Q144A and K+ influence 
 Q144 on helix α8 forms hydrogen bonds with backbone carbonyl groups of Y298 and 
F296 that are adjacent to S297, one of the residues that chelate to K+ in the active site. The 
highest specific activities under different conditions were observed with the Q144A mutant. 
Q144A had ~ 2-fold less activity reduction than wild type PDHK2 in a high salt buffer (Table 2-
2). These results suggested that Q144A responses to elevated levels of ions might be different 
from the native PDHK2.  
 To evaluate how K+ influenced the Q144A mutant, the responses of Q144A to increasing 
K+ were compared to those of wild type (Fig. 2-9, Fig. 2-10, Table 2-3). Q144A initially had a 
specific activity (~ 79 nmol⋅min-1⋅mg-1) lower than the wild type PDHK2 using E1 as substrate 
with 0.5 mM potassium phosphate. A nearly 2-fold increase in specific activity was observed 
with by 10 mM K+. In contrast, there was little change in wild type PDHK2 at this range of K+ 
(Fig. 2-9). Further increasing of K+ concentration led to the gradually decreasing of the specific 
activities of both Q144A and wild type kinase. Q144A underwent less activity loss (21%) 
beyond the peak at 10 mM K+ than wild type (58%) at 90 mM K+. To fully understand these 
profiles for changes in activity of wild type and Q144A with K+ level, more studies needed to be 
done to determine how the Vm and Km values for ATP and E1 change with different K+ levels. 
When E1•E2 was used as substrate, 3.5 mM KxPO4 (~ 6.5 mM K+) was initially 
introduced from E1 and E2. In the presence of E2, Q144A had a higher specific activity than 
wild type at all levels of K+ tested (Fig. 2-10). The specific activity of Q144A first increased by 
~ 20% with 10 mM K+ and then decreased at higher K+ levels. The specific activity of wild type 
PDHK2 decreased slowly but constantly with increasing K+. In the presence of E2, only small  
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Figure 2-9. K+ influence on the specific activities of wild type and Q144A PDHK2 using E1 as 
substrate. Open and closed circles show the changes in activities of wild type and Q144A 
PDHK2 respectively with K+ concentration. All assays were conducted in low salt buffer with 
0.5 mM KxPO4 introduced with E1. 
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Figure 2-10. K+ influence on the specific activities of wild type (open circle) and Q144A (closed 
circle) PDHK2 using E1•E2 as substrate. All assays were measured in low salt buffer with 3.5 
mM KxPO4 introduced with E1•E2.  
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decreases in activity of wild type PDHK2 were observed as K+ was raised to 90 mM, suggesting 
that the interaction with E2 stabilized PDHK2 activity. The specific activity of Q144A first 
increased and then decreased with increasing K+ concentration. These explained why high salt 
reduced the activity of Q144A less than wild type. It was not clear why kinase activity decreased 
at high levels K+. One possibility was the ion strength. This could be resolved using other ions 
such as Na+ to replace K+. Another possibility was that kinase was unstable under elevated K+ 
conditions especially with E1 as substrate. 
 The apparent Km and apparent Vmax of wild type PDHK2 for ATP were ∼ 58 µM and ∼ 
602 nmol⋅min-1⋅mg-1 using E1•E2 as substrate in a buffer containing 90 mM K+ (Fig. 2-11). 
Substitution of Q144 by Ala caused small increase on the apparent Km for ATP (∼ 68 µM) but 
the apparent Vmax for ATP increased more than 2-fold at ∼ 1012 nmol⋅min-1⋅mg-1 under this 
buffer conditions. 
In the above steady state activity studies, 100 µM ATP was present and ADP was 
produced during the reactions. Using K+-dependent fluorescence quenching linked to nucleotide 
binding, the binding of K+ to wild type and Q144A PDHK2 was studied (Fig. 2-12, Table 2-3). 
In the presence of 100 µM ATP, same levels of K+ resulted in substantially more fluorescence 
quenching with wild type PDHK2 than Q144A (Fig. 2-12). Half-maximal quenching (L0.5) for 
wild type kinase was estimated at ~ 1.3 mM K+ with 43% maximal quenching estimated under 
this condition (Table 2-3). Q144A required 12-fold higher K+ to reach the half-maximal 
quenching. These results suggested that replacement of Q144 by alanine weakened the binding 
of K+ to kinase in the presence of ATP and altered the capacity of ATP binding to quench the 
fluorescence of W383. The latter suggests that ATP/K+ binding at the active site is less effective 
in introducing conformational changes in the R domain. 
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Figure 2-11. Double reciprocal plot of the variation in initial velocities of wild type (open circle) 
and Q144A (closed circle) PDHK2 using E1•E2 as substrate. All assays were conducted in the 
low salt buffer with around 10 mM KxPO4 introduced with E1•E2. 
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Figure 2-12. Influence of K+ on fluorescence quenching of wild type and Q144A PDHK2 by 
ADP. All data were obtained at 350 nm in 50 mM Tris-Hepes buffer (pH 7.6) with excitation at 
290 nm. (Data were collected by Dr. Hiromasa, Y.)  
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Table 2-3. Nucleotide effects on K+ binding to wild type PDHK2 and Q144A. All parameters 
were derived from fluorescence quenching of 0.1 µM kinase by varying K+. Parameters were 
derived from a Hill plot analysis that assumed binding was proportional to fluorescence 
quenching. (Data were collected by Dr. Hiromasa, Y.) 
 
 
PDHK2 source Fixed ligands 
L0.5 for K
+  
(mM) 
Hill Coefficient, 
 nH 
Qmax (%) 
Wild type 100 M ATP 1.3 1 43 
Q144A 100 M ATP 17.2 0.74 20.4 
Wild type 200 M ADP 12 1 34.5 
Q144A 200 M ADP 14.3 1.2 15.7 
Wild type 
200 M ADP 
+ 20 mM Pi 
5.2 1.2 43 
Q144A 
200 M ADP 
+ 20 mM Pi 
9.6 1 27 
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The wild type PDHK2 binds K+ 10-fold tighter in the presence of ATP than ADP, 
suggesting that the γ-phosphate of ATP might play some role in the tighter binding of K+ (Table 
2-3).  On the contrary, there was no significant difference in the K+ binding in the presence of 
200 µM ADP with the estimated L0.5 for wild type and Q144A PDHK2 were 12.0 mM and 14.3 
mM separately. Addition of 20 mM Pi with ADP resulted in tighter binding of K+ to both wild 
type and Q144A PDHK2 and led to somewhat greater maximal quenching (Fig. 2-12B, table 2-
3). Under those conditions, K+ bound almost 2-fold tighter to wild type than to Q144A PDHK2. 
It is possible that Pi ion may occupy the same position as the γ-phosphate of ATP to result in 
tighter binding of K+ in the presence of ADP. Under all conditions, the maximal quenching for 
Q144A was less than that for wild type PDHK2. The difference might be due to the lower 
fluorescence of Q144A than wild type PDHK2 (Fig. 2-3). 
As would be expected for coupled K+/ATP binding (89), substitution of Q144 by alanine 
also weakened the binding of ATP based on fluorescence quenching studies (Table 2-4). Native 
kinase had an estimated L0.5 of 3.1 µM for ATP with ~ 45% maximal quenching in the saturated 
level of K+ (100 mM). Q144A needed 3-fold more ATP to reach the half-maximal quenching 
with an almost 2-fold lower maximal quenching. The lower maximal fluorescence quenching 
probably results, in part, from less W383 fluorescence of Q144A that would decrease the 
potential for ATP quenching of the Trp fluorescence of Q144A. Under the same condition, wild 
type PDHK2 bound ADP 23-fold weaker than ATP with no significant change in the maximal 
fluorescence quenching. Addition of Pi caused tighter binding of ADP (2-fold). There was no 
significant difference in the estimated L0.5 for ADP of Q144A and wild type PDHK2 in the 
presence or absence of Pi. These results suggested that signal transmission from the catalytic site 
to the cross arm anchoring W833 was changed with the mutation of Q144 to alanine. 
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Table 2-4. Nucleotide binding to wild type PDHK2 and Q144A. Binding of nucleotides to 0.1 
µM kinase was determined by measuring fluorescence quenching in the presence of 100 mM K+. 
Parameters were derived from a Hill plot analysis that assumed binding was proportional to 
fluorescence quenching. (Data were collected by Dr. Hiromasa, Y.) 
 
 PDHK2 source 
Pi 
(20mM) 
Nucleotide 
L0.5 for 
nucleotide 
( M) 
Hill Coefficient, 
nH 
Qmax (%) 
Wild type No ATP 3.1 1.7 47 
Q144A No ATP 9.9 1.1 26 
Wild type No ADP 72.0 1.0 43 
Q144A No ADP 77.1 0.9 24 
Wild type Yes ADP 35.0 1.1 45 
Q144A Yes ADP 39.3 1.0 32 
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 In conclusion, mutation of Q144 resulted in different response of PDHK2 to K+. The 
tighter binding of K+ in the presence of ATP was weakened. While the weaker K+ binding in the 
presence of ADP was not significantly reduced unless in the presence of Pi. Mutation of Q144 
also weakened the binding of ATP but not ADP (even with Pi) at the saturated level K+. 
Mutations in the DCA/pyruvate binding pocket  
 To examine the critical residues of putative DCA binding pocket identified from the 
crystal structure (76), several residues (R154C, I157F, R158A and R154C/L160A) in the α helix 
8 were mutated.  
 Fig. 2-13 shows the g(s*) profiles for selected mutants. Binding of GST-L2 to W383F, 
I157F and R154C gave faster sedimenting peaks due to complex formation (solid lines), with 
profiles similar to those previously reported for wild type PDHK2 (34). These results, in 
agreement with activity increase by E2, demonstrated that these mutants bound effectively to the 
L2 domain. For W383F and I157F, addition of 100 µM pyruvate plus 100 µM ADP decreased 
significantly the rate of sedimentation of fast moving peak (dot lines, Fig. 2-13). These results 
demonstrated that ADP plus pyruvate weakened the binding of GST-L2 to these mutants. On the 
other hand, the fast moving peak in R154C and GST-L2 mixture only underwent small changes 
upon addition of these ligands. These results suggest that ADP plus pyruvate caused little 
dissociation of GST-L2 from R154C, probably due to loss of pyruvate binding capacity in 
R154C as will be supported below. 
In potassium phosphate buffers, ADP caused fluorescence quenching of wild type 
PDHK2 (open circles, Fig. 2-14). Addition of 100 µM pyruvate caused the L0.5 of ADP to drop 
7.6-fold to 2.0 µM. At the same time, the maximal quenching also increased from 48% to 70% 
(closed circles, Fig. 2-14). These results suggest that ADP binds tighter to PDHK2 when  
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Figure 2-13. Sedimentation velocity analysis of binding of GST-L2 to selected mutants. In the 
absence (solid curve) and presence (dotted curve) of 100 µM ADP and 100 mM pyruvate, 
sedimentation velocity was conducted at 49,000 rpm at 20 °C using 3.7 µM kinase dimer and 7.5 
µM GST-L2 with the exception W383F (1.2 µM kinase dimer and 4.1 µM GST-L2). 
Sedimentation was monitored at 280 nm. (Data were collected by Dr. Hiromasa, Y. and 
published (for wild type PDHK2 and W383F) in J. Biol. Chem, (2006) 281, 12568-12579 (43)). 
Published data were reproduced with permission as covered under the general Copyright 
Permission Policy of J. Biol. Chem. 
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Figure 2-14. Fluorescence quenching of wild type PDHK2 or selected mutants by ADP in the 
absence (open circle) and presence (closed circle) of 100 µM pyruvate. All data were obtained 
with 0.7 µM kinase at 350 nm in potassium phosphate buffer with excitation at 290 nm. (Data 
were collected by Dr. Hiromasa, Y.) 
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pyruvate is also bound, in agreement with results from kinetic assays (40). The influence of 
pyruvate on ADP binding to mutants was also evaluated using fluorescence quenching (Fig. 2-
14). Pyruvate also enhanced binding of ADP to I157F, while there was no significant difference 
in the fluorescence quenching profiles of R154C and R154C/L160A. These results suggest that 
pyruvate binding was greatly weakened or lost with R154C and R154C/L160A mutation of 
PDHK2. 
 Table 2-5 shows the DCA inhibition of the mutants surrounding the pyruvate/DCA 
binding site. The activities were measured using E1•E2 as substrate in a high salt buffer. 0.1 mM 
or 1.0 mM DCA reduced the specific activity of the wild type PDHK2 by ~ 59% and ~ 86% 
separately. These levels of DCA caused similar activity reductions with I157F (44% and 84%). 
Therefore, replacement of I157 with phenylalanine did not significantly influence the DCA 
inhibition. For mutants R158A, R154C and R154C/L160A, DCA gave smaller or no inhibition. 
Those data again suggest that R154 and R158 are important for DCA inhibition.  
Ions and DCA inhibition 
 Buffers containing different combination of ions were used to evaluate how K+ and Cl- 
influenced the DCA inhibition of PDHK2 activity using E2 bound E1 as substrate (Fig. 2-15A). 
3.5 mM KxPO4 was introduced with E1 and E2 addition in all assays. In the low salt buffer, 0.1 
and 1.0 mM DCA caused ~ 22% and ~ 48% inhibition of wild type PDHK2 activities. Inclusion 
of 60 mM Cl- reduced the kinase activity up to 48%. At the same time, the DCA inhibitions were 
reduced to ~ 9% and ~25% separately. With addition of 90 mM K+, kinase activity was also 
decreased to 59% of the initial value; while DCA inhibition was greatly enhanced, giving 2.7- 
and 1.8- fold greater inhibition with those levels of DCA. The combination of both K+ and Cl- 
further reduced kinase activity to 34%. The DCA inhibition was only ~ 7% with 0.1 mM DCA  
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Table 2-5. DCA inhibition of wild type PDHK2 and mutants using E1•E2 as substrate. All 
assays were conducted in duplicate with 8.6 µM kinase in high salt buffer in the presence of E2 
and 100 µM ATP at 30 °C. 
 
 
DCA (mM) Wild type R154C R154C/L160A R158A I157F
0 285±10 185±8 161±5 181±12 219±5
0.1 118±2 169±4 178±12 182±8 122±18
1.0 41±2 175±9 197±10 148±1 36±2
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Figure 2-15. Influence of ions on DCA inhibition of wild type PDHK2 and I157F using E1•E2 
as substrate. All the assays were measured with 9.5 nM native PDHK2 or 16 nM I157F. DCA 
was added 1 min before 100 µM ATP. The basic buffer used was the low salt buffer with around 
3.5 mM KxPO4 introduced with E1 and E2. 
Ion conc.  K+      none     none       90         90             K+   none     none       90         90 
    (mM)    Cl-      none       60       none       60             Cl-   none       60        none      60 
 
W
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and ~ 59% with 1.0 mM DCA. The DCA inhibition was greater than with Cl- alone but less than 
with K+ alone with 1.0 mM DCA. These results demonstrated that DCA inhibition was enhanced 
by K+ and decreased by Cl- using E1•E2 as substrate. This kinetic result for K+ influence was in 
agreement with what got from fluorescence quenching studies, in which 100 µM ADP had no 
influence on pyruvate binding in the absence of K+ while pyruvate bound to 14-fold tighter to 
PDHK2 in the presence of K+ (89). 
 The influence of ions on DCA inhibition of mutant I157F was also evaluated using 
E1•E2 as substrate (Fig. 15B). I157F had a specific activity of ~ 647 nmol⋅min-1⋅mg-1 in a low 
salt buffer. Under theseconditions, 0.1 mM and 1.0 mM DCA inhibited the activity of I157F by 
39% and 70% respectively, both higher than the inhibition of native kinase by the same levels of 
DCA. The specific activity of I157F decreased 75% with the addition of 60 mM Cl-, which was 
1.5-fold more reduced than native kinase. At the same time, the DCA inhibition was also 
decreased to 7% with 0.1 mM DCA or 12% with 1.0 mM DCA, both of which were lower than 
the inhibition of native kinase by same levels DCA. With the addition of 90 mM K+ into the low 
salt buffer, the specific activity of I157F decreased by 66%, again 1.6-fold larger than the native 
kinase, with a small increase in inhibition (44% by 0.1 mM DCA and 84% by 1.0 mM DCA). 
The combination of both Cl- and K+ ions caused 80% loss of the specific activity of I157F with 
inhibition of 15% by 0.1 mM DCA and 57% by 1.0 mM. Based on these results, it appears that 
both K+ and Cl- had larger initial effects on I157F mutant than on wild type PDHK2. Again, the 
increased K+ or Cl- inhibition may be due none specific ion effects on the stability of I157F. K+ 
enhanced the inhibition of I157F by DCA but by a smaller degree than wild type PDHK2. At the 
same time, Cl- reduced the inhibition of I157F by DCA by a larger degree than wild type 
PDHK2. 
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Pyruvate/DCA inhibition using E1 alone as substrate 
 The direct influence of pyruvate on kinase activity was measured using E1 alone as 
substrate (Fig. 2-16). To minimize the influence of K+ and Cl-, no extra K+ or Cl- was added 
apart from the initial potassium phosphate (~ 10 mM) introduced with E1. The specific activity 
of wild type PDHK2 decreased with increasing pyruvate (Fig. 2-16). Because R154C had lower 
specific activity under these conditions, its inhibition by pyruvate was not conducted. Therefore, 
pyruvate directly inhibited PDHK2 activity apart from causing the dissociation of lipoyl groups 
as was known (32). With 100 µM ATP, ~ 110 µM pyruvate was required to inhibit 50% activity 
of wild type PDHK2. Mutants W383F and I157F had inhibition patterns by pyruvate similar to 
native kinase. The replacement of Q144 with alanine somehow decreased the inhibition by 
pyruvate, requiring ~ 250 µM pyruvate to reach 50% inhibition with ~ 85% being the maximal 
inhibition.  
In general, these mutations did not abolish pyruvate inhibition. On the contrary, pyruvate 
caused little or no inhibition with R158A and R154C/L160A even up to 1.0 mM (Fig. 2-16). 
These results indicate that R154 and R158 play important roles in the pyruvate binding.  
The DCA inhibition profiles are shown in Figure 2-17, using E1 as substrate under low 
salt conditions. Compared with pyruvate, same levels DCA caused less maximal inhibition to 
wild type PDHK2. Q144A, I157F and W383F mutants had DCA inhibition patterns similar to 
that of the wild type PDHK2. In agreement with the lack of pyruvate inhibition, R154C/L160A 
and R158A mutants were not inhibited by up to 2.0 mM DCA. These results from DCA 
inhibition again suggest R154 and R158 play important roles in the DCA/pyruvate binding. 
 Using AUC, fluorescence quenching, and activity inhibition studies using E1 alone or 
E1•E2 as substrate, it was found that mutations of R154 and R158 weakened or abolished the 
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Figure 2-16. Pyruvate inhibition of wild type and mutants PDHK2 using E1 alone as substrate. 
Panel A shows the change of specific activity with pyruvate. Panel B shows the change of 
percentage of activity left. All assays were conducted with 43 nM kinase dimer in low salt buffer 
with 10 mM KxPO4. 
 
A B 
 69 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2-17. DCA inhibition of wild type and mutants PDHK2 using E1 alone as substrate. Panel 
A shows the change of specific activity of the kinase with increasing DCA. Panel B shows the 
change in the percentage of activity left. All assays were conducted with 43 nM kinase dimer in 
low salt buffer with 10 mM KxPO4. 
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DCA/pyruvate binding capacity and resulted in little or no DCA/pyruvate inhibition. Therefore, 
R154 and R158 are important residues for DCA/pyruvate binding to human PDHK2, which is 
consistent with the crystal structure (76). DCA or pyruvate caused not only the dissociation of L2 
from the kinase (if combined with ADP) but also directly inhibited the phosphorylation of 
substrate E1. The finding that replacement of I157 by Phe did not reduce inhibition of PDHK2 
suggests this difference may not be the major reason for weaker pyruvate inhibition of PDHK3 
(see discussion for the reasons).  
The importance of R154 and R158 of human PDHK2 in the DCA/pyruvate inhibition 
was contradicted to previous studies on rat PDHK2, in which R154A and R158A had similar 
DCA inhibition as the wild type PDHK2 (85). As Cys has a bigger side chain than Ala, it was 
possible (although unlikely) that loss of DCA/pyruvate inhibition of human R154C was due to a 
physical interference to binding of DCA/pyruvate instead of due to lacking of specific Arg side 
chain. Further mutation of R154 to Ala would help to resolve such difference between human 
and rat PDHK2.  
Cl- inhibition on PDHK2 and mutants 
 Using E1 alone as substrate, the effects of Cl- on PDHK2 activity were evaluated (Fig. 2-
18). Increasing Cl- levels decreased the activity of wild type PDHK2. I157F, Q144A and W383F 
generally responded like wild type kinase with increasing Cl-. It required ~ 21 mM Cl- to reach 
50% inhibition for those mutants and native kinase. The specific activities of R158A and 
R154C/L160A were less sensitive to Cl-. It required 2-fold more Cl- (~ 56 mM) to reach 50% 
inhibition. These data suggest that mutation of R154 and R158 also weakened the influence of 
Cl-. 
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Figure 2-18. Cl- inhibition of wild type and mutants PDHK2 using E1 alone as substrate. Panel A 
shows the change in specific activity with Cl- concentration. Panel B shows the change of 
percentage of activity. All assays were conducted with 43 nM kinase in a low salt buffer with 10 
mM KxPO4.  
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Using E1•E2 as substrate, Cl- effects on R158A and R154C/L160A were also evaluated 
(Fig. 2-19). Compared with using E1 alone as substrate, Cl- reduced kinase specific activities of 
these constructs less in the presence of E2. Wild type PDHK2 activity was reduced only ~ 10% 
by 10 mM Cl- in the presence of E2, a 1/3 fold less than that using E1 alone as substrate. 60 mM 
Cl- resulted ~ 50% activity reduction of wild type PDHK2. The specific activities of R158A and 
R154C/L160A were decreased little by 10 mM Cl-. Both R158A and R154C/L160A retained 
greater fractions of their initial specific activities than wild type at 60 mM Cl-. These data again 
suggest that replacements of R154 and R158 result in reduced kinase sensitivity to Cl- inhibition. 
It was not clear why Cl- reduced the activity of R154C/L160A and R158A at high levels using 
E1 or E1•E2 as substrate. Further experiment was required to determine if non-specific ion 
effects cause it or there is a second Cl binding site.  
Relationship between Cl- and pyruvate inhibition 
 Cl- hindered the inhibition of PDHK4 by DCA (Dong, et. al, unpublished data). The 
above studies showed PDHK2 had reduced DCA inhibition in the presence of Cl-. The mutants 
that lacked pyruvate inhibition also had reduced sensitivity to Cl- with or without E2, while those 
mutants that maintained pyruvate inhibition also had greater Cl- sensitivity as wild type PDHK2. 
These finding suggested that there might be a specific connection between pyruvate inhibition 
and the Cl- response. One possibility is that Cl- may bind to PDHK2 at the same pocket as 
DCA/pyruvate. If that was true, they should compete against each other. To examine this 
concept, pyruvate inhibition was measured in the presence of different levels of Cl- using E1 as 
substrate (Fig. 2-20, Table 2-6). Addition of Cl- lowered the initial kinase activities. Increasing 
pyruvate decreased PDHK2 activity gradually with or without Cl- (Fig. 2-20). The same levels of 
pyruvate gave less inhibition with increasing Cl- levels. The estimated IC50 was ~ 81 µM in the  
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Figure 2-19. Cl- inhibition on native and mutants PDHK2 using E1•E2 as substrate. Panel A 
shows the change of specific activity with Cl- concentration. Panel B shows the change of 
percentage of activity. All assays were conducted with 10 nM kinase dimer in a low salt buffer 
with 13 mM KxPO4. 
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Figure 2-20. Cl- influence on pyruvate inhibition of native PDHK2 using E1 as substrate. Solid 
lines show the changes of specific activity. Dashed line show the change of percentage of 
inhibition of the initial activities. All assays were conducted with 43 nM kinase dimer in low salt 
buffer with 10 mM KxPO4. 
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 Table 2-6. Effects of Cl- and Nov3r on pyruvate inhibition using E1 alone as substrate. 
Inhibition of kinase was measured using 100 µM ATP. The parameters were derived from a Hill 
plot analysis. Assay conditions were described under the materials and methods. *, 2% DMSO 
was present in all assays. 
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absence of Cl- (Table 2-6). Addition of 5 and 10 mM Cl- increased the IC50 for pyruvate 
inhibition by 1.3- and 1.7-fold separately. As predicated by competition at the same site, PDHK2 
approached the same activity as pyruvate was increased to 400 µM no matter the initial 
concentration of Cl-. This is expected with competition at same site due to bound Cl- being 
replaced by pyruvate. These results agree with the proposal that Cl- and pyruvate inhibitions are 
not independent and suggest that they bind to the same site on PDHK2. 
 Form the studies of Cl- effects, it was found that the R154 and R158 are important 
residues for Cl- inhibition. Cl- binds to the DCA/pyruvate site of human PDHK2 and competes 
with DCA/pyruvate to reduce their inhibition. 
Stimulation of PDHK2 
 The influences of reductive acetylation were evaluated for several mutants (Fig. 2-21). 
The assay buffers included 90 mM K+, 60 mM Cl- and 20 mM extra Pi. This buffer is used 
because both the presence of elevated K+ and the inhibitory anions are required for stimulation 
(30). In these assays, the ratio of NADH to NAD+ was fixed 3:1 to prevent the conversion of E3 
to the fully reduced (dithiol-FADH2) form. The mutants with higher initial activities were 
stimulated less (Fig. 2-21). NADH/NAD+ increased the activity of wild type PDHK2 by1.7-fold. 
The activity increased 3.9-fold with both NADH/NAD+ and 50 µM acetyl-CoA. Both R154C 
and R158A underwent similar extents of stimulation as wild type, indicating that replacement of 
both residues interfering with pyruvate binding had no influence on stimulation by reductive 
acetylated lipoyl groups which bind at the adjacent lipoyl group binding site. W383F also had 
similar stimulatory response as wild type. Double mutant R154C/L160A had less NADH/NAD+ 
and Acetyl-CoA stimulation (1.6- and 2.3-fold). Q144A, which had highest initial activity, had 
the lowest amount of stimulation (1.7-fold) by reductive acetylation (Fig. 2-21). These data  
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Figure 2-21. Stimulation of wild type and mutants PDHK2 by NADH and acetyl-CoA. 
NADH/NAD+ ((0.6/0.2 mM) was added 60 s before 100 µM ATP and 50 µM acetyl-CoA was 
added 20 s before ATP. Other assay conditions were described in the materials and methods.
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suggest that both L160 and Q144 may participate in the signal transmission from the lipoyl 
group binding site to the catalytic site. 
Nov3r & PDHK2 activity using E1 as substrate 
 Nov3r is a PDHK2 inhibitor that inhibits E2-enhanced kinase activity (83, 84). Based on 
the crystal structure, Nov3r binds at the same site as the lipoyl group (76, 77). By competing 
with lipoyl prosthetic groups, Nov3r prevents PDHK2 binding to lipoyl domain of E2, resulting 
in loss of E2 activated kinase function (76). Using free E1 as substrate, the influence of Nov3r to 
kinase was evaluated (Fig. 2-22).  
 2% DMSO, which caused less than 8% reduction of kinase activity, was added to all 
assays. In a low salt buffer containing 10 mM KxPO4, binding of Nov3r increased PDHK2 
activity with a maximal increase of ~ 20% by 100 nM Nov3r (Fig. 2-22). The estimated 
concentration to reach the half maximal stimulation was ~ 60 nM Nov3r. It was reported that 
Nov3r bound to PDHK2 with an affinity less than 10 nM under high salt buffers (88). The Kd for 
Nov3r binding was not determined under a low salt condition. However, it appeared that Nov3r 
bound to PDHK2 less tightly under low salt than high salt conditions. It was possible that the 
maximal activity increase by Nov3r might occur with single Nov3r bound per PDHK2 dimer. 
Further experiments would be needed to evaluate this possibility. Higher Nov3r levels caused a 
gradual decrease of kinase specific activity. These results were similar to previous studies with 
GST-L2 and ΔBE2 (lacking E1 binding domain) in which kinase activity was activated at low 
levels of effectors but was inhibited by higher levels (30, 32). These data agree with the 
conclusions that Nov3r binds to lipoyl group binding site of PDHK2. 
Pyruvate weakens the binding of the lipoyl domain to PDHK2. The influence of pyruvate  
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Figure 2-22. Nov3r influence on wild type PDHK2 using E1 alone as substrate. Data showing 
with circle, square and triangle were obtained with no inhibitor, 100 µM pyruvate and 20 mM Cl- 
respectively. All assays were conducted in low salt buffer with 10 mM KxPO4.  
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or Cl- to Nov3r effects was investigated (Fig 2-22). 100 µM pyruvate reduced PDHK2 activity 
by ~ 60%. Nov3r gave a 115% maximal increase of activity at 200 nM Nov3r, but this activity 
was still 15% lower than the original PDHK2 activity in the absence of both pyruvate and Nov3r. 
Therefore, Nov3r reduced but did not abolish pyruvate inhibition. The concentration needed to 
reach half-maximal activity was estimated to be ~ 100 nM Nov3r, a ~1.5-fold higher than in the 
absence of pyruvate. Higher levels of Nov3r also slightly lowered kinase activity (Fig. 2-22). As 
Cl- might occupy the same site as pyruvate based on its competing with pyruvate (above results), 
it was reasonable to suggest that Nov3r binding to PDHK2 might also have a similar effect in 
reducing Cl- inhibition. In the presence of 20 mM Cl-, PDHK activity dropped to 43%, similar to 
the effect of 100 µM pyruvate. However, Nov3r caused a much smaller increase (~20%) and 
then a gradual decrease in the kinase activity; a pattern more closely resembling that without Cl- 
than that in the presence of pyruvate (Fig. 2-22). The estimated concentration to reach the half-
maximal activity was ~ 75 nM Nov3r. Therefore, the influence of Nov3r on the inhibitory effects 
of pyruvate and Cl was different. The cause of Nov3r inhibition at higher levels was not clear. 
I also studied how ions influenced the effects of Nov3r on pyruvate/DCA inhibition using 
E1 alone as substrate (Fig. 2-23). 1.0 µM Nov3r caused ~10% reduction in kinase activity in 
buffers tested. One possibility was that PDHK2 lost activity during a half hour gap because it 
was not stable when mixed with E1 alone. The specific activity of PDHK2 was reduced ~ 60% 
or 45%, respectively, by either 90 mM K+ or 20 mM Pi in the presence or absence of 1.0 µM 
Nov3r. Therefore, Nov3r did not significantly influence the extent of inhibition by K+ and Pi. In 
a low salt buffer (0.4 mM potassium phosphate from E1), 100 µM pyruvate or 200 µM DCA 
inhibited PDHK2 activity by ~ 23% and 24%. Addition of Nov3r did not significantly change the 
inhibition by either inhibitor (~19% by pyruvate and ~ 27% by DCA). Inclusion of 20 mM Pi  
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Figure 2-23. Ion effects on Nov3r influence to inhibition of wild type PDHK2 by pyruvate or 
DCA using E1 as substrate. 1.0 µM Nov3r, 200 µM DCA or 100 µM pyruvate were added 60 s 
before 100 µM ATP. The indicated levels of Pi and K+ were added into assay buffers.  
 
 
 
Nov3r                -  -  -  + + +       -   -  -  + + +       -  -  -  + +  +      -  -  -  +  +  + 
K+          none           none  90 mM 90 mM 
Pi          none          20 mM   none  20 mM 
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inhibited but had minimal effects on pyruvate (~25%) and DCA (~15%) inhibition. Nov3r 
caused small reduction in the low inhibition by pyruvate and DCA to 12 and 10%, respectively 
with this buffer. Addition of 90 mM K+ caused 2-fold greater inhibition by both pyruvate and 
DCA than was observed with the low salt buffer. Nov3r had an increased capacity to reduce 
pyruvate inhibition but did not significantly reduce the DCA inhibition. In a buffer containing 
both K+ and Pi, activity of PDHK2 was even lower (~ 30% of that in low salt buffer). At the 
same time, pyruvate and DCA were potent inhibitors giving ~ 81% and ~ 69% activity decreases 
respectively. Although addition of Nov3r, alone, modestly inhibited PDHK2 activity, Nov3r 
hindered pyruvate inhibition (3.7-fold rise in activity) and gave a smaller but substantial removal 
of DCA inhibition (1.9-fold rise in activity). These results indicated that just as pyruvate and 
DCA inhibition and binding are enhanced by K+ and Pi, the capacity for Nov3r to block these 
effects is also fortified by these ions.  
The effects of Nov3r on pyruvate inhibition were further assessed over a wide rage of 
pyruvate concentrations in a buffer containing 90 mM K+ and 20 mM Pi (Fig. 2-24, table 2-6). 
At all levels of pyruvate, less kinase was observed in the presence than in the absence of 1.0 µM 
Nov3r (Fig. 2-24). Pyruvate maximally inhibited kinas activity up to ~93% with an estimated 
IC50 of ~ 28 µM without Nov3r (Table 2-6). Addition of 1.0 µM Nov3r weakened the pyruvate 
inhibition with an ~ 4-fold increase of the IC50 and 82% maximal inhibition. It needed to be 
noted that the IC50 without Nov3r was almost 3-fold higher than that in the buffer containing 10 
mM KxPO4. It indicated that pyruvate inhibition was enhanced by elevated K+ and Pi even using 
E1 alone as substrate. 
Based on above studies of Nov3r effects, it can be concluded that binding of Nov3r to 
human PDHK2 increased kinase activity. Nov3r binding at the lipoyl group binding site reduced  
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Figure 2-24. Influence of Nov3r on pyruvate inhibition of wild type PDHK2 using E1 as 
substrate. The changes of activity and percentage of inhibition are shown in solid and dashed 
curve respectively. The data with closed and open circle were obtained with or without Nov3r 
respectively. 1.0 µM Nov3r and pyruvate were added 60 s before 100 µM ATP. The assays were 
conducted with 2% DMSO in low salt buffer with 90 mM K+ and 20 mM Pi added.  
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the DCA/pyruvate inhibition at the nearby DCA/pyruvate site. Even though Cl- binds to the same 
site as DCA/pyruvate, Nov3r did not significantly affect its inhibition relatively because of the 
smaller size of Cl-. 
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Discussion 
 Fluorescence quenching of the cross arm anchoring W383 with ligands binding—
(Published in J. Biol. Chem. (2006) 281 12568-12579 (43)) Based on the crystal structure of 
human apo-PDHK2 dimer, a cross arm was formed by the C-terminal residues 361-384 of each 
subunit that extends from the Cat domain of one subunit to interact primarily via Trp383 with the 
dimerization face of the R-domain of the second subunit (Fig. 1-5, 76). Similar cross arms are 
observed in the crystal structures of human PDHK3•L2 and these cross arms plus the extended 
C-terminal tail contribute to the binding of lipoyl domain (77). The cross arm is not resolved in 
the crystal structure of human PDHK2•ADP•DCA (76). ADP or ATP alone interferes slightly 
with the binding of PDHK2 to E2 or L2 (43). AUC studies revealed that pyruvate plus ADP 
prevented binding of GST-L2 to PDHK2 and that PDHK2 dimers associated as tetramers under 
these conditions (34, 36, 43). To reduce PDHK2 association with L2, ligand binding may cause 
conformational changes in PDHK2 that alter the cross arm stability. That possibility is supported 
by ligand-induced changes in Trp383 fluorescence. 
W383F-PDHK2 maintained the capacity to bind to E2 lipoyl domains and its activity was 
enhanced by E2. W383F had only one-third of the intrinsic fluorescence intensity of the native 
kinase at 350 nm. Even though PDHK2 contains three Trp, the loss of Trp fluorescence with 
W383F suggests that Trp383 provides most of the Trp fluorescence of wild type PDHK2. ADP 
or ATP caused fluorescence quenching of the native kinase did not influence the fluorescence of 
the W383F mutant, indicating that ADP or ATP binding at the active site significantly alters 
W383 interactions at the R-Cat domain interference that is occurring more than 20 Å from the 
active site. The fluorescence quenching of W383 confirmed that conformational changes 
happened to the cross arm-anchoring Trp environment with the binding of ADP or ATP because
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the fluorescence of tryptophan is sensitive to the change of its electrostatic environment (81, 82). 
But it is still not clear how the cross arm changes with ligand binding. This may involve with 
ATP or ADP binding small conformational shifts around the Trp anchoring region with an 
increased probability of breaking free of the cross arm.  
Pyruvate quenched the fluorescence of not only wild type PDHK2 but also W383F, but to 
a substantially reduced extent. Therefore, pyruvate binding at the DCA/pyruvate site resulted in 
conformational changes to the Trp383 environment. The residual quenching of W383F suggests 
that the surrounding environment of at least another Trp was also changed. Trp79 is located in 
helix α5 of the R domain next to Tyr80 and directly above His115, which sits above bound 
DCA/pyruvate (Fig. 1-6, 76). Both Trp79 and His115 shift with ADP and DCA bound (76). 
Interactions of Trp with a histidine side chain can cause Trp fluorescence quenching (81, 82). 
The fluorescence intensity of Trp371 may not change much with the binding of ligands as it is 
exposed to solvent on the cross arm. 
ADP binds tighter to PDHK2 with bound pyruvate, as much lower concentration of ADP 
were required to reach same level of fluorescence quenching of PDHK2 in the presence of 
pyruvate. The reciprocal was also true that ADP greatly enhanced pyruvate binding. These 
results are consistent with kinetic studies that ADP dissociation was slowed by pyruvate (40). 
The increased fluorescence quenching by pyruvate plus ADP may occur with the disruption of 
the cross arm that leads to dissociation of L2 from kinase and formation of PDHK2 tetramer (34, 
36, 43). 
Basis for pyruvate/DCA inhibition—Crystallographic studies identified a DCA binding 
site on PDHK2. Based on structural considerations, it would appear that the carboxyl group of 
DCA forms a salt bridge with R154 and that R158 controls the access of DCA into the binding 
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pocket (76). It is reported that mutation of R154A and R158A of rat PDHK2 did not significantly 
affect the DCA inhibition although rat PDHK2 has exact same sequence at the R domain as 
human PDHK2 (85). The finding was carried out with my studies and as described below these 
findings are not with my studies seeking to determine the roles of these residues in 
DCA/pyruvate inhibition of human PDHK2. Previous studies reported that DCA/pyruvate 
strongly inhibited PDHK2 but weakly inhibited PDHK3 (32). Human PDHK2 and PDHK3 have 
generally conserved residues forming the proposed DCA/pyruvate binding site. A difference 
includes substitution of Ile157 by Phe in PDHK3. In the crystal structure of human PDHK2 (76), 
I157 has hydrophobic interactions with DCA. In apo-PDHK2, there is a large space between 
I157 and I111/His115 that is occupied by the side chain of Phe in human PDHK3 (77) with 
substitution of I157F by Phe and I111 by Val. It is possible that the single substitution causes 
weaker pyruvate/DCA inhibition in PDHK3 (32).  
R154C and R158A mutants at the DCA/pyruvate site and the double mutant 
R154C/L160A maintained the capacity to bind to E2 lipoyl domains based on retention of E2-
activation of kinase activity and similar GST-L2 binding observed by AUC studies. DCA or 
pyruvate gave little inhibition of these mutant kinases using E1 alone or E1•E2 as substrate. 
AUC data confirmed that pyruvate did not cause significant dissociation of GST-L2 from these 
mutants. Unlike with native PDHK2, pyruvate did not affect the binding of ADP to these 
mutants based on the fluorescence quenching studies. These results suggest that pyruvate or 
DCA did not inhibit the kinase activity due to lack of inhibitor binding with the mutation of 
R154 or R158. Therefore, R154 and R158 residues of human PDHK2 play important roles in 
DCA/pyruvate recognition. 
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The other mutation at this site, I157F, displayed inhibition patterns by pyruvate or DCA 
similar to wild type PDHK2. Pyruvate could also bind to I157F based on the pyruvate 
interference with this mutant binding to GST-L2 in AUC studies and pyruvate-enhanced 
fluorescence quenching profiles by ADP. Based on these results with PDHK2, the Phe residue in 
this position in native PDHK3 may not be the reason for weaker inhibition of PDHK3 by 
DCA/pyruvate. However, the weaking of inhibition of inhibition by the resident Phe in PDHK3 
is not eliminated since crowding of the DCA binding space by this Phe is observed with native 
PDHK3 crystal structures but is not observed for Ile of native PDHK2 structures. PDHK2 may 
accommodate the Phe substitution with retention of an open inhibitor binding space. Other 
possible causes will be considered below. 
The results of pyruvate/DCA binding site mutation in human PDHK2 were very different 
from recent reports with rat PDHK2 (85). In rat PDHK2, both R154A and R158A were inhibited 
by DCA, while DCA caused even stronger inhibition to rat I157A. It also needed to be noted that 
rat L160A was active. It was possible (although unlikely) that the difference between R154C in 
human and R154A in rat was due to the larger side chain of Cys blocking the binding of DCA or 
pyruvate. The basis for such different results with R158A and L160A substitutions are not well 
understood, as human and rat PDHK2 have identical sequences in the R domain. 
Pyruvate plus ADP weaken the binding of lipoyl domains to PDHK2 (43). Thus, 
pyruvate/DCA inhibition of E2-enhanced kinase activity is probably, in part, due to increased 
dissociation of PDHK2 from the lipoyl domains of E2. This would decrease the access of 
PDHK2 to E1 substrate that also binds to E2 through E1-binding domains. It was reported that 
DCA inhibited PDHK2 in the absence of E2 although the inhibition was significantly weaker 
than with E2 (32). A critical condition in those studies was inclusion of high level Cl- (see 
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below). Our studies on human PDHK4 also found that pyruvate/DCA directly inhibited kinase 
activity using E1 alone as substrate (unpublished data from our lab). Using E1 alone as substrate 
with a low Cl- buffer, my studies found that pyruvate directly inhibited the phosphorylation of E1 
with an estimated IC50 of ~ 91 µM, which indicates tight pyruvate binding. DCA also inhibited 
PDHK2 but the inhibition was weaker than pyruvate under these conditions. With E1•E2 as 
substrate, inhibition probably results from this direct effect and also from decreased access of 
kinase to E1 substrate due to inhibitor-enhanced dissociation of kinase from the lipoyl domains 
of E2. For PDHK2, DCA or pyruvate causes marked losses of kinase activity (using E1•E2 as 
substrate) because these inhibitors act on PDHK2 by both mechanisms. Due to tight binding to 
E2, the capacity of these inhibitors to reduce PDHK3 binding to E2 may be minimal. Lack of 
this effect may contribute to the less effective inhibition of this isoform either by reducing the 
maximal inhibition of PDHK3 or by reducing the affinity of pyruvate/DCA. Studies on PDHK3 
inhibition by pyruvate/DCA using E1 in the absence of Cl- are needed. 
Mechanism for Cl- inhibition—Most of the reported assays of kinase activity were 
performed using elevated levels Cl- (at least 60 mM). Cl- is one of the ions that reduce the 
activity of wild type PDHK2 and Cl- inhibition is overcome as part of stimulation by reductive 
acetylation (30, 32, 40). My studies found that Cl- weakened the DCA inhibition of E2-enhanced 
kinase activity. Using E1 alone as substrate, increasing levels of Cl- reduced the specific 
activities of wild type PDHK2. It required ~ 21 mM Cl- to drop the initial activity to 50% with an 
estimated maximal inhibition ~ 90%. Using E1 alone as substrate, both the R154C/L160A and 
R158A mutants, which had weakened DCA/pyruvate inhibition, also had greatly reduced 
inhibition by Cl-. Two-fold higher Cl- levels were required to reach 50% inhibition of these 
mutant kinases. Cl- inhibited R154C/L160A and R158A less than native kinase in the presence 
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of E2 suggesting that both Arg residues also play important roles in Cl- inhibition. With wild 
type PDHK2, the estimated IC50 for pyruvate increased 1.7- and 2.2-fold in the presence of 5 
and 10 mM Cl-. The full set of data could be fit by a model in which Cl- binds to the same site 
and competes with pyruvate/DCA. Cl- may form electrostatic interactions with R154 and R158 
side chains in binding to PDHK2. Substitution of either amino acid would weaken the binding of 
Cl- thereby causing less inhibition. The competition between Cl- and DCA explained why 
reported DCA inhibition (32) was weaker in a MOPS-K+ buffer, which containing 60 mM Cl-, 
comparing with my results in a buffer with minimal Cl-. 
DCA caused more activity decrease when using E1•E2 as substrate than using E1 alone 
as substrate in a buffer with minimal Cl-. On the contrary, Cl- inhibited the activity of PDHK2 
less using E1•E2 as substrate than using E1 alone as substrate under same conditions. It 
appeared that Cl- was not as efficient as DCA in causing dissociation of L2 from PDHK2. This 
agrees with the AUC studies that found GST-L2 was dissociated from PDHK2 by pyruvate plus 
ADP (43) but not by Cl- plus ADP (unpublished data from our lab).  The binding of lipoyl group 
to kinase probably stabilized the kinase and weakened the Cl- inhibition. Previous studies of 
DCA inhibition on PDHK3 were conducted in buffers containing 60 mM Cl- (32). That may be 
another reason for weak DCA inhibition of E2-enhanced kinase activity of PDHK3. In fact, 
1mM DCA gave 55% inhibition of PDHK3 activity in a buffer that contained a low level of Cl- 
(unpublished data from our lab). It needs to be noted that substitution of I157F at the 
DCA/pyruvate site enhanced Cl- inhibition. When comparing the crystal structures of PDHK2 
(76) with PDHK3 (77), the larger side chain of Phe appears to occupy more space at where DCA 
bound than Ile. Possibly, decreased space at this site may strengthen Cl- binding. 
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Linkage from the R domain to the Cat domain —K+ decreases the Km for ATP and Ki for 
ADP of PDHK and specifically PDHK2 (32, 80). In the presence of E2, elevated K+ slows the 
dissociation of ADP from PDHK2 thereby also decreasing kinase activity (32, 40). Recent 
studies on PDHK2 (89) quantified large effects of K+ in the tight ATP/ADP binding, ADP 
enhanced pyruvate binding, and Pi enhanced ADP/pyruvate binding. In the crystal structures of 
BCKD kinase and human PDHK3, a K+ ion is found coordinated at the active site with ATP or 
ADP (73, 77). Based on the branched-chain kinase structure, a K+ was modeled in a similar 
position in the active site of PDHK2 crystal structures (76). 
 In the apo-structure of PDHK2, the backbone carbonyl groups of Leu295, Ser297, 
Gly319 and hydroxyl group of Ser301 form the binding pocket for K+. With ADP/DCA bound, 
the α-phosphate of ADP also chelates K+. Based on the crystal structures, with bound ATP and 
Nov3r, hydrogen bonds formed by the backbone NH groups of Gly317 and Tyr320 with the 
oxygen atom that link the β and γ phosphate and the oxygen atom of γ-phosphate occur with an 
associated conformational changes around K+ binding pocket that prevent the interactions 
between K+ and C=O groups of Gly319 (Fig. 2-25) (76). As these crystal structures were 
obtained not only with different bound effectors (DCA or Nov3r) but also with ADP or ATP 
bound, respectively, it is still unknown whether binding of ATP versus ADP also contributed to 
changes at the active site. Based on the fluorescence quenching studies, it was observed that K+ 
was bound 16-fold tighter in the presence of ATP than ADP, and 2-fold tighter K+ binding was 
observed with ADP plus Pi. Therefore, binding of ATP or ADP alone probably favored different 
conformational states at the active site to result in different affinities in binding of K+. Pi may 
occupy the same position as γ-phosphate of ATP and bring similar changes to the binding pocket 
of K+ in the presence of ADP, resulting in tighter binding of K+. Pi effects on pyruvate binding  
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Figure 2-25. Linkage from the R domain to the catalytic site.  Q144 and N140 residues on α8 
helix of the R domain of PDHK2 link the R domain with loop 295-298 of the Cat domain 
through hydrogen bonds between N140-S297, Q144-Y298 and Q144-F296. K+ ion is connected 
to the loop by interactions with S297 and L295. Finally, the K+ interacts with the α-phosphate of 
ATP/ADP to complete the linkage from the R domain to the catalytic site. In the presence of 
ATP, K+ also interacts with S301. In the presence of ADP or apo-PDHK2, G319 is also involved 
in the K+ binding. 
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were observed even with bound ATP (89). It is possible that Pi has another binding site in 
PDHK2. The binding of K+ with ADP or ATP at the active site was specific, as Na+ did not 
influence the ADP/ATP binding (89). It was also reported that NH4+ bound to PDHK2 even 
tighter than K+ in the presence of ATP (89).  
 The side chain of Q144 in the α-helix 8 of R domain forms hydrogen bonds with 
backbone NH of Tyr298 and backbone C=O group of Phe296, residues adjacent to Ser297 that 
chelate K+  via C=O group (Fig. 2-25) (76). The substitution of Q144 would abolish the 
hydrogen bonds, thus might lead to conformational changes in the ADP/ATP•K+ binding site via 
repositioning of the 296-298 segment with altering S297 chelation of K+. The specific activities 
of native kinase decreased with increasing K+ concentration with or without E2. Using E1 alone 
as substrate, the specific activity of Q144A increased 2-fold when K+ was increased from 0.9 
mM to 10 mM, followed by a 21% reduction with K+ increasing further to 90 mM. Similar 
trends were also observed for Q144A with less initial increase and less decrease in the presence 
of E2. Fluorescence quenching also confirmed the changes of K+ binding with mutation of 
Q144A. Q144A mutation weakened the K+ binding affinity by 15-fold in the presence of ATP 
but gave no change in the presence of ADP unless Pi was included. With 100 mM K+, ATP 
binding was 3-fold weaker due to substitution of Q144 with Ala. Therefore, Q144 at the R 
domain is an important residue that affects the binding of K+ and coupled ATP or ADP at the 
active site in the Cat domain.  
 Nov3r binding and pyruvate inhibition— Based on the crystal structures of PDHK3, L2 
binding involved the binding of lipoyl prosthetic group by mostly hydrophobic interactions and 
by mostly electrostatic interactions between the C-terminal tail of PDHK3 and L2 domain (77). 
Mutations at the lipoyl group-binding site resulted in less stimulation of PDHK3 by L2 (79). As 
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described in introduction, Nov3r binds at lipoyl goup binding site in human PDHK2. Nov3r is 
probably an analog of acetyl-dihydrolipoyl group (86). This compound and the related AZD7545 
inhibit E2-activated kinase activity through preventing binding of lipoyl domains to kinase (77, 
83, 84, 88). It was reported that L2 or ΔBE2 increased kinase activity less than 30% (32, 40). 
Using E1 alone as a substrate, binding of Nov3r to kinase caused maximally a 20% activity 
increase with 100 nM Nov3r and the kinase activity decreased with higher levels Nov3r under a 
low salt buffer. Therefore, over a narrow concentration range, Nov3r mimics the lipoyl domain 
structures in activating kinase activity although the former activities were performed with a high 
salt buffer. 
Based on crystal structures of PDHK2 (76), the Nov3r binding site is adjacent to the 
DCA binding site. Therefore, binding of ligand at one site may affects ligand binding at the other 
site. With PDHK2 inhibited by 100 µM pyruvate, Nov3r enhanced kinase activity, suggesting 
that Nov3r binding was hindering pyruvate binding and inhibition at the nearby site. It needs to 
be noted that kinase activity increased maximally 2-fold, which was still 15% less than the initial 
activity without pyruvate under these low salt conditions. This indicates that Nov3r substantially 
reduced but did not eliminate the inhibitory effects of pyruvate. Varying the level of pyruvate 
with or without Nov3r established that probably the affinity for pyruvate was reduced but the 
maximal inhibition was also decreased somewhat. 
In studies where salt conditions were varied and inhibition by pyruvate or DCA 
compared with the effects of Nov3r, strong DCA or pyruvate inhibition required both elevated 
K+ and also elevated Pi. This result was in agreement with results from fluorescence quenching 
studies, in which Nov3r interfered the tighter binding of ADP•pyruvate•PDHK2 via a Pi 
dependent mechanism (88). In the presence of both K+ and Pi, Nov3r reduced the weaker DCA 
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inhibition less effectively than it reduced the stronger pyruvate inhibition. Although my results 
indicate that Cl- binds to the same site as pyruvate/DCA and inhibits kinase activity, Nov3r did 
not efficiently reduce Cl- inhibition. Therefore, Nov3r influence in reducing inhibition at the 
pyruvate/DCA site might depend on the size of the inhibitor. Binding of Nov3r to the lipoyl 
group-binding site may allosterically cause specific conformational changes at pyruvate/DCA 
binding site. The changes may be small as inhibition by the larger pyruvate is weakened but not 
the inhibition by the much smaller Cl-. Additionally, increasing of the size of inhibitors at the 
pyruvate/DCA site may tighten the coupled binding of ADP/ATP•K at the catalytic site to lead 
to conformational changes at the cross arm to reduce binding of lipoyl domain. These data are 
consistent with the findings that pyruvate plus ADP prevent binding of GST-L2 to kinase (43) 
but their association was not significantly influenced by Cl- plus ADP as compared to ADP alone 
(Hiromasa, Y., unpublished data).  
Communication from ligand binding site on the R domain to the active site—Reducing of 
the lipoyl groups of E2 by E3 using NADH/NAD+ increases E2-enhanced PDHK2 activity. 
Acetylation of reduced lipoyl groups by E3 using acetyl-CoA results in even bigger increases in 
kinase activity. These effects could only be observed with elevated levels of ions. The 
stimulation by reductive acetylation was small with L2 and bigger with tightly bound GST-L2 
(21, 30, 32). Nov3r/lipoyl group binding pocket is formed by L23, Q27, F28, F31, T40, S41, 
F44, L45, L160, Q163, H164, I167 and F168. The CF3 group of Nov3r sits close to the side 
chain of L160 at a location (Fig. 2-26) where it is estimated by structural analog analysis that the 
CH3 of acetyl group of 8-acetyl-DHL-Lys would be positioned (86). It was anticipated that 
substitution of L160 with alanine might increase the distance from the CH3 group to the side 
chain of L160 and thereby weaken the interactions of acetylated dihydrolioyl-Lys with the end of  
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Figure 2-26. Signal transmission from the lipoyl group (Nov3r) binding site to the catalytic site. 
Nov3r appears to be an analog of acetyl-dihydrolipoyl-lys. Nov3r binds to a hydrophobic site in 
the R domain. This is also the binding site for the lipoyl groups of lipoyl domain. The 
information from the reductive acetylation may be transferred to helix α8 by interactions 
between the CH3 group of acetyl and side chain of L160. The signal is then transfer to Q144 or 
N140 along helix α8. Through the hydrogen bonds, the signal is further transferred to the loop 
295-298 of the Cat domain. Finally, the signal reaches the catalytic site with the interactions by 
loop 295-298 with K+ and K+ with α-phosphate of ADP or ATP. 
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the binding pocket, resulting in less stimulation. The double mutant R154C/L160A underwent 
significantly lower stimulation by reductive acetylation. As R154C was stimulated to an extent 
similar as native kinase, the smaller activity increase of R154C/L160A likely resulted from 
mutation of L160A. This suggests that the communication from lipoyl group binding site to 
active site was changed by mutation of L160 although some impact of R514C mutation cannot 
be eliminated. L160A of rat PDHK2 was active with no significantly altered binding capacity to 
L2 domain (87). But these authors did not evaluate whether stimulation by reductive acetylation 
was altered with rat L160A-PDHK2 using E1•E2 as substrate. 
Helix α8 spans the whole R domain of PDHK2 (76). Its C-terminus is involved in the 
binding of lipoyl group (L160, Q163, H164, I167 and F168). The adjacent DCA/pyruvate 
binding site has several residues from α8 (S153, R154, I157 and R158). At the N-terminal end of 
helix α8, N140 forms a hydrogen bond with S297 from the Cat domain and Q144 provides two 
hydrogen bonds with F296 and Y298 from the Cat domain. As emphasized above, S297 appears 
to interact with K+ in active site. These hydrogen bonds may provide a linkage between helix α8 
of R domain and the catalytic site through bound K+ at the active site. Therefore, it is possible 
that helix α8 plays a particularly important role in communication between these sites at the R 
domain and the active site.  
Mutation of Q144A weakened the binding of K+. This cross arm anchoring Trp inserts 
between R149, L152 in helix α8 and R362 (76). It was reported that reductive acetylation 
enhanced PDHK2 activity by increasing the rate of ADP dissociation (30). Reductive acetylation 
stimulated activity of Q144 only half of that with native PDHK2. The major change was a higher 
control activity that is consistent with weaker K+ binding allowing faster ADP dissociation (rate 
limiting step) in the absence of stimulation. The final dissociate rates were similar. Therefore, 
N
ov3r 
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Q144 might be involved in the signal transmission from the lipoyl site to the active site. A 
possible communication pathway from lipoyl group binding site to active site is: acetylated 
lipoyl group···Leu160···helix α8···Gln144···loop 296-301···K+•ADP/ATP (Fig 2-26). Specifically 
in native PDHK2, this may result in weakened K+ binding that, in turn, could allow faster 
dissociation of ADP. The residential stimulation of Q144A mutant by reductive acetylation 
indicates that communication probably involves other residues in different pathways. One 
residue involved is probably N140 that also linked helix α8 with the Cat domain through 
hydrogen bond with F296. 
Steady-state kinetic assays and binding studies measured by fluorescence quenching or a 
cold trap approach indicated that pyruvate/DCA binding was tighter to PDHK2•ATP but much 
tighter to PDHK2•ADP (40, 43). Fluorescence studies confirmed that binding of ADP or ATP 
enhanced the binding of inhibitors while pyruvate also tightened the binding of ADP but not 
ATP in potassium phosphate buffers (43). DCA inhibits PDHK2 by slowing down the 
dissociation of ADP (40). It was reported that K+ enhanced the DCA inhibition on kinase (40) 
and that K+ and Pi enhanced the binding of pyruvate with ADP (88). My studies confirmed that 
K+ enhanced the DCA/pyruvate inhibition of PDHK2 using not only E1•E2 but also E1 alone as 
substrate. Pyruvate/DCA weakly inhibited the kinase activity in a buffer containing minimal 
levels of ions. One possible reason is that ADP or ATP signal transmission from the 
DCA/pyruvate site to the active site may involve the bound K+. Mutation of Q144A resulted in 
somewhat weaker pyruvate inhibition using E1 alone as substrate. Therefore, Q144 may play 
some roles in the communication from DCA/pyruvate site to the active site. To better understand 
this communication, more studies would be required. 
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Conclusions—Through studying mutants of several residues in the R domain of PDHK2, 
there were several new findings about the molecular mechanisms by which PDHK2 kinase is 
regulated. 1) Binding of ATP or ATP at the catalytic site in the Cat domain caused mostly the 
fluorescence quenching of W383 that was lost with W383F mutant. W383 anchors the cross arm 
and provides the majority of intrinsic Trp fluorescence of PDHK2. The sensitive fluorescence 
change of the structurally defined Trp residue was used to evaluate changes in ligand binding. 
Pyruvate, binding to DCA/pyruvate site, caused the fluorescence quenching of not only W383 
but also other Trp (W79). Therefore, ligand binding resulted in changes of the electrostatic 
environment surrounding W383. But it is still unclear what caused the fluorescence quenching: a 
smaller shift around this region or a total opening up of the cross arm. 2) Mutation of Q144 
resulted in a different response of PDHK2 to K+ ion level. Q144 residue in the α8 helix of the R 
domain may serve as an important linkage between the R domain and the Cat domain. This 
linkage involves the K+ ion that binds with ATP or ADP to the ATP/ADP binding site. 3) 
Residues R154 and R158 at the DCA/pyruvate site play important roles in the DCA/pyruvate 
inhibition (for both the dissociation of lipoyl domains and inhibition of phosphorylation of 
substrate E1). 4) Cl- ion binds specifically to the DCA/pyruvate site and competes with DCA or 
pyruvate to reduce their inhibition. 5) Substitution of I157 by Phe did not reduce PDHK2 
inhibition by pyruvate, DCA or Cl-. Therefore, the Phe residue in PDHK3 may not be the major 
reason for the reported weaker inhibition of PDHK3 by DCA. One reason these inhibitions may 
be less effective with PDHK3 is that the tighter binding of lipoyl domains to PDHK3 does not 
allow the inhibitors to reduce activity by hindering binding to E2.  6) Residues L160 (through 
interaction at the lipoyl group binding site) and Q144 (linkage between the R domain and the Cat 
domain) appear to be important for lowering control activity with elevated ions which is 
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overcome in stimulation by reductive acetylation. This suggests these residues contribute to 
conformations that aid lowering of control activity and /or removal of diminished activity during 
stimulation. And 6) Binding of Nov3r at the lipoyl group binding site reduced the inhibition at 
the nearby DCA/pyruvate site with diminishing effects as the size of the inhibitors decreases. 
Overall, this thesis established that fluorescence quenching of W383 could be used to 
evaluate the ligand binding and uncovered specific residues in helix α8 of the R domain that 
contribute to pyruvate/DCA inhibition, K+-linked signal transduction within PDHK2 structure 
and stimulation by reductive acetylation. This thesis provided new insight that Cl- reduces 
PDHK2 activity by binding at the pyruvate/DCA binding site.  This thesis also supported that 
binding of Nov3r at the lipoyl group binding site hindered the inhibition at the nearby 
DCA/pyruvate site in a manner that requires specific ions such as K+ and Pi and diminishes with 
the size of the inhibitors. These novel insights advance the understanding the molecular 
mechanisms regarding how ligand binding to the R domain modulates the catalytic use of ATP 
in the Cat domain. 
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